Exploitation of Ebola Virus VP35 Protein to identify new drugs counteracting its type I IFN antagonism by unknown
                   
 
UNIVERSITÀ DEGLI STUDI DI CAGLIARI 
 
DOTTORATO DI RICERCA 
Scienze e Tecnologie Farmaceutiche 
Ciclo XXVII 
 
 
 
Exploitation of Ebola Virus VP35 Protein to Identify New Drugs 
Counteracting its Type I IFN Antagonism 
Settore scientifico disciplinare di afferenza 
Microbiologia BIO/19 
 
 
 
Relatore: 
Prof. Enzo Tramontano       
 
Correlatore: 
Prof. Elias Maccioni 
                                                                                                                    
Coordinatore Dottorato: 
Prof. Elias Maccioni 
 
 
 
Presentata da: 
Dott.ssa Valeria Cannas
 
Esame Finale Anno Accademico 2013 – 2014  
 
2 
 
Abstract 
Ebolaviruses (EBOVs) are among the most virulent and deadly pathogens ever known, causing 
fulminant haemorrhagic fevers in humans and non-human primates. The 2014 outbreak of Ebola virus 
disease (EVD) in West Africa has claimed more lives than all previous EVD outbreaks combined. The 
EBOV high mortality rates have been related to the virus-induced impairment of the host innate 
immunity reaction due to two virus-coded proteins, VP24 and VP35. EBOV VP35 is a multifunctional 
protein, it is essential for viral replication as a component of the viral RNA polymerase and it also 
participates in nucleocapsid assembly. Early during EBOV infection, alpha-beta interferon (IFN-α/β) 
production would be triggered upon recognition of viral dsRNA products by cytoplasmic retinoic acid-
inducible gene I (RIG-I)-like receptors (RLRs). However, this recognition is efficiently prevented by the 
double-stranded RNA (dsRNA) binding activity of the EBOV VP35 protein, which hides RLRs binding 
sites on the dsRNA phosphate backbone as well the 5’-triphosphate (5’-ppp) dsRNA ends to RIG-I 
recognition. In addition to dsRNA binding and sequestration, EBOV VP35 inhibits IFN-α/β production 
preventing the activation of the IFN regulatory factor 3 (IRF-3) by direct interaction with cellular 
proteins. Previous studies demonstrated that single amino acid changes in the VP35 dsRNA binding 
domain reduce EBOV virulence, indicating that VP35 is an attractive target for antiviral drugs 
development. Within this context, here we report the establishment of a novel method to 
characterize the EBOV VP35 inhibitory function of the dsRNA-dependent RIG-I-mediated IFN-β 
signaling pathway in a BLS2 cell culture setting. In such system, a plasmid containing the promoter 
region of IFN-β gene linked with a luciferase reporter gene was transfected, together with a EBOV 
VP35 mammalian expression plasmid, into the IFN-sensitive A549 cell line, and the IFN-induction was 
stimulated through dsRNA transfection. Through alanine scanning mutational studies with 
biochemical, cellular and computational methods we highlighted the importance of some VP35 
residues involved in dsRNA end-capping binding, such as R312, K282 and R322, that may serve as target 
for the development of small-molecule inhibitors against EBOV. Furthermore, we identified a synthetic 
compound that increased IFN-induction only under antiviral response stimulation and subverted VP35 
inhibition, proving to be very attractive for the development of an antiviral drug. In conclusion, our 
results provide the establishment of a new assay as a straightforward tool for the screening of 
antiviral compounds that target i) dsRNA-VP35 or cellular protein-VP35 interaction and ii) dsRNA-
dependent RIG-I-mediated IFN signaling pathway, in order to potentiate the IFN response against 
VP35 inhibition, setting the bases for further drug development.  
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1.0. INTRODUCTION 
1.1. Ebola virus 
1.1.1. Classification and taxonomy 
Ebolaviruses (EBOVs) constitute a group of filamentous, enveloped, non-segmented viruses that 
owns a single and negative-stranded RNA genome with the characteristic gene order 3´- UTR - 
core proteins genes - envelope protein genes - polymerase gene - 5´- UTR. The genus Ebolavirus, 
along with Marburgvirus and Cuevavirus, belong to the family Filoviridae, order of 
Mononegavirales. The family name is derived from “filum”, which is Latin for thread, reflecting the 
agents unique filamentous morphology (Kuhn et al. 2010) (Fig. 1b). Since the discovery, in 1967, of 
Marburg virus as the first member of the group, classification and taxonomy of filoviruses have 
changed continuously and the criteria used refer to the most updated terminology with which 
EBOVs are currently known, named and classified (Kuhn et al. 2010). The family Filoviridae, located 
in the order Mononegavirales, is positioned among the Paramyxoviridae, Rhabdoviridae and 
Bornaviride viral families, which all share similar organization in their negative-sense, single-
stranded RNA (ssRNA-) genome. The family Filoviride actually comprises three genera, 
Marburgvirus, Ebolavirus and Cuevavirus, which are all antigenically different. The genera 
Marburgvirus and Cuevavirus include each only one single viral species, namely Marburg 
marburgvirus (MARV) and Lloviu cuevavirus (LLOV) respectively, while the genus Ebolavirus 
comprises five distinct species: Bundibugyo ebolavirus (BDBV), Zaire ebolavirus (EBOV), Reston 
ebolavirus (RESTV), Sudan ebolavirus (SUDV) and Taï Forest ebolavirus (TAFV) (Fig. 1a). According 
to the rules for taxon naming established by the International Committee on Taxonomy of Viruses 
(ICTV), the name of the genus Ebolavirus is always to be capitalized, italicized, never abbreviated, 
and to be preceded by the word "genus". The names of its members (ebolaviruses) are to be 
written in lower case, are not italicized, and used without articles (Kuhn et al. 2010). 
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a  
b  
Figure 1. Taxonomy and morphology of Ebolaviruses. (a) Current classification of Ebolaviruses according to the 8th 
Report of the International Committee on Taxonomy of Viruses (ICTV), with the most recently proposed changes in 
classification and nomenclature (Kuhn et al. 2010) as well as in phylogenetic relationship (Barrette et al. 2011). (b) A 
transmission electron micrograph shows the ultrastructural morphology displayed by an Ebola virus virion (CDC - 
Frederick A. Murphy). 
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1.1.2. Epidemiology of Ebola virus disease 
The first recorded outbreaks of Ebola virus disease (EVD), that showed the symptoms of a severe 
haemorrhagic fever, occurred in June 1976 in southern Sudan (now South Sudan) and in July 1976 
in the vicinity of a mission hospital in Yambuku, Zaire (now Democratic Republic of the Congo, 
DRC) (Deng et al. 1978; Burke et al. 1978; Bres 1978). Although the outbreaks occurred at a similar 
time and in the same geographical area of central Africa (Yambuku is ~500 km from Nzara), no 
definite link between them was established, and later virological studies demonstrated 
differences between the two strains, subsequently described as the Sudan and Zaire strains 
(McCormick et al. 1983; Richman et al. 1983). The Sudan outbreak began in the town of Nzara, 400 
km from the regional capital Juba, and affected workers in a cotton-processing factory. A 
symptomatic case was transferred to the district hospital of Maridi, where explosive nosocomial 
transmission occurred. Within four weeks, one-third of the 220 hospital staff had acquired 
infection, and 41 had died. At this time, there was no knowledge of the mode of transmission of 
this ‘new’ disease, and no effective infection control activities or personal protective equipment 
(PPE) were available. Maridi hospital acted as an amplifier for cases in the community, and by the 
end of the outbreak in October there had been 284 cases and 151 deaths. Two months after the 
first case in Nzara, a similar disease became apparent in a mission hospital in Yambuku, Zaire. The 
initial infections occurred in patients who had attended the outpatient clinic of the hospital. 
Parenteral injections with syringes not sterilized between patients, from an initial unsuspected 
index case, were presumed to be the route of transmission. Subsequent transmission then 
occurred within the hospital and from infected patients into the community. A total of 318 known 
cases occurred, with 280 deaths, a case fatality rate of 88%. Eleven of the 17 nursing/clinical staff 
of the hospital died. No patient whose contact was exclusively parenteral injection survived. 
Investigations indicated that the index case had eaten bush meat during recent forest travel. 
Because of the dramatic nature of the illness and the clinical symptoms that resembled those 
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observed during another haemorrhagic fever-like disease, occurred in 1967 in Marburg, Frankfurt 
(Germany) and in Belgrade (former Yugoslavia), the two African outbreaks were initially 
suspected to be caused by MARV, the viral agent that had been incidentally transmitted to 
laboratory workers from tissues of infected monkeys imported from Uganda, causing 31 human 
infections in Europe, with 7 deaths. The two outbreaks occurred in Sudan and Zaire in 1976, 
however, were soon found to be caused by two new filoviruses, detected and isolated from 
clinical samples collected during the outbreaks. Morphologically similar to MARV but antigenically 
distinct from it, the name “Ebola virus”, Sudan and Zaire subtypes, was respectively attributed to 
them after the small river Ebola, headwater if the Mongala river, a tributary of Congo river 
(former Zaire), that flows past Yumbuku (Kuhn 2008).  
Following the 1976 Sudan and Zaire outbreaks, there have been 18 documented EVD outbreaks in 
central Africa, and one isolated case in Côte d’Ivoire (in 1974). Epidemiologically, these outbreaks 
fall into three main groups: those occurring in remote forest areas, linked directly to bush meat 
consumption, and usually with relatively few cases; those centred around and within regional 
hospitals, with considerable hospital transmission, spreading into the community; and those 
occurring in populated rural areas, with mainly community transmission but some transmission in 
local health facilities. No EVD outbreaks were reported between 1979 and 1994, but after 1994 the 
number of recognised outbreaks increased. In November 1994, a wave of infections hit three 
gold-mining camps in Gabon, from which the virus spread with a wave of secondary and tertiary 
cases among villages along the border with Cameroon. Overall, 52 infections occurred, with 32 
deaths (mortality rate of 60%) (Pourrut et al. 2005). An isolated case of Ebola infection occurred in 
Côte d’Ivoire in 1994 (Formenty et al. 1999) in an expatriate zoologist after undertaking an 
autopsy on a chimpanzee in the Tai forest area. The zoologist was repatriated and survived. 
Virology studies showed the strain to be different from those of Sudan and Zaire, and was 
designated Ebola Tai forest strain (Le Guenno et al. 1995). Forest area outbreaks have occurred in 
Gabon, Republic of the Congo and DRC (Formenty et al. 2003; Nkoghe et al. 2005; Rouquet et al. 
 
10 
 
2005; Nkoghe et al. 2011). With the exception of two large, extended, outbreaks in Republic of the 
Congo and DRC, reported case numbers ranged from 12 to 65, and case fatality rates from 57% to 
83%. One outbreak in DRC was closely associated with fruit bat migration and consumption (Leroy 
et al. 2009; Grard et al. 2011). Two large outbreaks have occurred linked to regional hospitals, in 
DRC in 1995 and in Uganda, 2000 (Khan et al. 1999; Centers for Disease Control and Prevention 
(CDC) 2001; Lamunu et al. 2004). The outbreak in DRC occurred in Kikwit, a 350-bed regional 
hospital, resulting in infection in 80 healthcare workers (though some may have been infected in 
the community), and subsequent spread to other hospitals following patient transfer (Ndambi et 
al. 1999; Muyembe-Tamfum et al. 1999). The Uganda outbreak, in Gulu district, was centred on 
two hospitals and the surrounding communities. There were 425 cases and 224 deaths, including 
17 hospital staff. Many of the community cases were associated with attendance at burials. The 
outbreak spread to another area 150 km distant when a patient was transferred to another 
hospital (Borchert et al. 2011). Outbreaks in rural communities with some health facilities 
involvement have occurred in South Sudan and Uganda with case numbers ranging from 6 to 34 
except for an extended outbreak in DRC (Baron et al. 1983; Onyango et al. 2007; Shoemaker et al. 
2012; Albariño et al. 2013). In 2007 a new strain of Ebola virus was isolated in an outbreak in 
Bundibugiyo district of Uganda, resulting in 147 reported cases, but a lower case fatality rate than 
with Zaire or Sudan strains (Wamala et al. 2010; MacNeil et al. 2010; Roddy et al. 2012). An 
outbreak caused by the same strain (now termed the Bundibugyo strain) occurred in DRC in 2012, 
though no links were discovered between the two areas (World Health Organization (WHO) 
2012). 
On March 21, 2014, the Guinea Ministry of Health reported the outbreak of an illness characterized 
by fever and severe diarrhoea, with a case fatality rate of 59% in the first 49 cases notified. 
Specimens from 15 of the patients tested were positive for Ebola virus, Zaire strain (Dixon & 
Schafer 2014). By March 30th, cases were reported in a neighbouring area of Liberia, and in May, 
the first cases in Sierra Leone occurred. By the middle of June, the outbreak had become the 
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largest EVD outbreak ever reported, with a total of 528 cases and 337 deaths. By August 8th, 
there had been a total of 1848 cases and 1013 deaths, spread between the three countries and a 
small travel-related cluster in Nigeria, and an international public health emergency was declared 
by WHO (Briand et al. 2014). A number of studies have investigated the possible origin of the 
outbreak. It was established that the first case, linked through a chain to the cases reported in 
Guinea on March 21st, was a child in the Gueckedou region of south-eastern Guinea who died on 
December 6th, 2013 (WHO Ebola Response Team 2014). Virology studies have subsequently 
confirmed that the virus is the Zaire strain, with 97% homology with earlier strains from DRC and 
Gabon (Baize et al. 2014). At February 10, 2015, the total reported case number for Guinea, Sierra 
Leone, and Liberia was 22859, and 9162 deaths (Centers for Disease Control and Prevention (CDC) 
2015a). The global dimension of the West Africa outbreak has been demonstrated by the 
transmission of infection to healthcare workers in hospitals in Europe and the USA, from index 
cases repatriated from Liberia (Parra et al. 2014; McCarty et al. 2014) (Fig. 2 and Table 1). 
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Figure 2. Locations of Ebolavirus infections and outbreaks. Geographic distribution of Ebolavirus natural human 
outbreaks reported worldwide, as of February 2015. Locations are pointed with pins according to the color-coded and 
different sizes legend for Ebolavirus species and number of cases, respectively (Centers for Disease Control and 
Prevention (CDC) 2015b). 
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Table 1. Outbreaks Chronology: Ebola Virus Disease. Known cases and outbreaks of Ebola Virus Disease, in reverse 
chronological order (Centers for Disease Control and Prevention (CDC) 2015b). 
Year(s) Country Ebola subtype Reported 
number of 
human cases 
Reported 
number (%) of 
deaths among 
cases 
August-November 2014 Democratic Republic of the Congo Zaire virus 66 49 (74%) 
March 2014-Present Multiple countries Zaire virus 23406 9457 (40%) 
November 2012-January 2013 Uganda Sudan virus 6* 3* (50%) 
June-November 2012 Democratic Republic of the Congo Bundibugyo virus 36* 13* (36.1%) 
June-October 2012 Uganda Sudan virus 11* 4* (36.4%) 
May 2011 Uganda Sudan virus 1 1 (100%) 
December 2008-February 2009 Democratic Republic of the Congo Ebola virus 32 15 (47%) 
November 2008 Philippines Reston virus 6 
(asymptomatic) 
0 
December 2007-January 2008 Uganda Bundibugyo virus 149 37 (25%) 
2007 Democratic Republic of the Congo Ebola virus 264 187 (71%) 
2004 Russia Ebola virus 1 1 (100%) 
2004 Sudan (South Sudan) Sudan virus 17 7 (41%) 
November-December 2003 Republic of the Congo Ebola virus 35 29 (83%) 
December 2002-April 2003 Republic of the Congo Ebola virus 143 128 (89%) 
October 2001-March 2002 Republic of the Congo Ebola virus 57 43 (75%) 
October 2001-March 2002 Gabon Ebola virus 65 53 (82%) 
2000-2001 Uganda Sudan virus 425 224 (53%) 
1996 Russia Ebola virus 1 1 (100%) 
1996 Philippines Reston virus 0 0 
1996 USA Reston virus 0 0 
1996 South Africa Ebola virus 2 1 (50%) 
1996-1997 (July-January) Gabon Ebola virus 60 45 (74%) 
1996 (January-April) Gabon Ebola virus 37 21 (57%) 
1995 Democratic Republic of the Congo 
(formerly Zaire) 
Ebola virus 315 250 (81%) 
1994 Côte d'Ivoire (Ivory Coast) Taï Forest virus 1 0 
1994 Gabon Ebola virus 52 31 (60%) 
1992 Italy Reston virus 0 0 
1989-1990 Philippines Reston virus 3 
(asymptomatic) 
0 
1990 USA Reston virus 4 
(asymptomatic) 
0 
1989 USA Reston virus 0 0 
1979 Sudan (South Sudan) Sudan virus 34 22 (65%) 
1977 Zaire Ebola virus 1 1 (100%) 
1976 England Sudan virus 1 0 
1976 Sudan (South Sudan) Sudan virus 284 151 (53%) 
1976 Zaire (Democratic Republic of the 
Congo - DRC) 
Ebola virus 318 280 (88%) 
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 1.1.3. Nature reservoirs and life cycle of EBOVs 
EVD is a zoonotic disease, and the viruses implicated in human outbreaks are thought to originate 
in live or dead animals (Pourrut et al. 2005). The circulation of the virus among humans is 
insufficiently understood, possibly explaining the sporadic nature of the outbreaks (Fauci 2014). 
Despite advances in understanding the molecular biology and the pathogenesis of filoviruses, 
identifying the reservoir from where the virus spills into humans and non-human primates, and 
understanding the factors that facilitate this process, remain challenging (Groseth et al. 2007; 
Negredo et al. 2011). It was proposed that either the reservoir is a rare species, or that 
transmission within the reservoir itself is not efficient (Feldmann et al. 2004). In most Ebola virus 
outbreaks, the source of the infection in the index case has not been determined. Examples are 
the 1976 outbreaks , the 1995 Mekouka and Kikwit outbreaks, 1996 Bouée outbreak  and other 
subsequent outbreaks from Sudan and Uganda (Pourrut et al. 2005). In several other human 
Ebola virus outbreaks, such a number from Gabon and the DRC, human infections occurred 
concomitantly with an increased mortality among non-human primates, such as gorillas and 
chimpanzees (Rouquet et al. 2005; Muyembe-Tamfum et al. 2012). In 1994, an ethnologist became 
infected in Côte D’Ivoire after performing an autopsy on a chimpanzee that died during an 
outbreak in the Taï National Park (Le Guenno et al. 1995; Muyembe-Tamfum et al. 2012). In a 1994 
outbreak that affected gold-diggers from Minkebé, Gabon, which was initially confused with 
yellow fever, people killed a sick gorilla for food (Amblard et al. 1997; Muyembe-Tamfum et al. 
2012). Prior to the 1996 Mayibout outbreak in Gabon, children found and butchered a chimpanzee 
carcass in the forest, and in several subsequent outbreaks it was documented that prior to 
developing disease, people handled animal carcasses that they found (Pourrut et al. 2005; Le 
Guenno et al. 1995). Since non-human primates are also susceptible to the infection, they are 
considered to be intermediate hosts (Georges et al. 1998). Several studies attempted to identify 
the natural reservoir of the filoviruses. Even though over 8000 vertebrates and 30,000 
invertebrates have been captured and tested for the presence of the virus since the first reported 
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EVD outbreaks in 1976, the reservoir for the infection remains elusive (Pourrut et al. 2007). Small 
animals, reptiles, arthropods and plants were proposed, at various times and by various authors, 
as likely reservoirs involved in transmitting the Ebola and Marburg viruses (Feldmann et al. 2004; 
Ascenzi et al. 2008). Several lines of evidence point towards the possibility that fruit bats could be 
the natural reservoir of the Ebola virus (Weingartl et al. 2012), and it is conceivable that a different 
reservoir exists for each of the Ebola virus subtypes (Georges et al. 1998; Feldmann et al. 2004). 
One of these pieces of evidence is the observation that in some outbreaks, such as the 1995 
outbreak from Kikwit (the DRC), the 2007 outbreak from Mweka (the DRC), the 2000 outbreak 
from Gulu (Uganda) and the 2004 outbreak from Yambio (Sudan), the hunting and eating of fruit 
bats was linked to the human outbreaks (Muyembe-Tamfum et al. 2012). As a result of these 
observations, several studies proposed to examine evidence of Ebola virus infection in bats and in 
other species. Although Ebola virus has never been isolated from bats in the wild, the detection of 
the virus in bats by PCR and serologic evidence indicates that they may be a reservoir for the 
Ebola virus (Takada 2012; Bausch & Schwarz 2014). The possibility that bats may be a reservoir for 
the virus is also supported by many studies on the Marburg virus infections (Towner et al. 2009; 
Amman et al. 2012). Demonstrating direct transmission from putative reservoirs, such as bats, is 
difficult because of the nature of bat bites, which are often invisible and painless, but evidence for 
this route, even though circumstantial, is powerful (Feder et al. 1997; Oczkowski 2007; Edson et al. 
2011; Johnson et al. 2014). Bats, also known as ‘flying foxes’, the only known flying mammals in 
the world, and among the most ancient of the mammals, inhabit all continents except Antarctica, 
and represent almost 25% of the recognised mammal species (Calisher et al. 2006; Omatsu et al. 
2007). Bats live on average 3.5-times longer than a mammal of similar size, promoting the 
persistence of the virus in the host and increasing the likelihood of transmission (Hayward et al. 
2013; Smith & Wang 2013). This, along with other characteristics, such as bat migration and their 
population structure and migration patterns, make them particularly suitable reservoirs for 
viruses (Calisher et al. 2006; Stein 2015).  
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EBOVs transmission likely begins unidirectionally (Fig. 3), with reservoirs bats chewing and 
sucking the pulp of certain fruits, thereby contaminating them with their saliva. Masticated fibres 
or urine and feces may then contaminate the ground as bats feed, and such partially eaten fruits 
and wastes may be consumed in the tree canopy or in the ground by highly susceptible secondary 
hosts, including gorillas, chimpanzees, monkeys, duikers and rodents. Once infected, accidental 
hosts can sustain virus transmission through both intra-specific and inter-specific direct contacts. 
Human infection may occur after hunting, butchering and consumption of bushmeat from one of 
these hosts, or, alternatively, through contaminated fruits by bats excreta. Hence, human-to-
human transmission can be repeatedly sustained within the wave-like spread of an outbreak 
(Pourrut et al. 2005; Groseth et al. 2007; Gonzalez et al. 2007). 
 
 
Figure 3. Mechanism of Ebolavirus transmission in nature. (a) Proposed virus reservoir: fruit bats. The virus maintains 
itself in fruit bats. The bats spread the virus during migration. (b) Epizootic in primates. Infected fruit bats enter in 
direct contact with other animals and pass on the infection, sometimes causing large-scale epidemics in gorilla, 
chimpanzees and other monkeys or mammals (e.g. forest antelopes). (c) Primary human infection. Humans are infected 
either through direct contact with infected bats (rare event), or through handling infected dead or sick animals found in 
the forest (more frequent). (d) Secondary transmission. Secondary human-to-human transmission occurs through 
direct contact with the blood, secretions, organs or other body fluids of infected persons. High transmission risk when 
providing direct patient care or handling dead bodies (funerals). 
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1.1.4. Clinical manifestation of EVD 
The clinical manifestations of EVD were described during the initial outbreaks in DRC and Sudan in 
1976; more details were reported for a large number of patients after the 1995 Kikwit epidemic, 
and shorter descriptions have appeared for subsequent outbreaks (Bwaka et al. 1999; Kortepeter 
et al. 2011). It seems that different species of EBOV might cause somewhat different clinical 
manifestations. Generally, EVD is a severe acute viral illness often characterized by the sudden 
onset of fever followed by a 2-3-day initial period with non-specific symptoms: fever, severe 
headache, muscle pain, intense weakness, sore throat, and sometimes conjunctive injection. This 
is followed by a 2-4-day deteriorating period with severe sore throat, chest and abdominal pain, 
maculopapular skin rash on the trunk and shoulders, diarrhoea, vomiting, impaired kidney and 
liver function, and in some cases both internal and external bleeding (Fig. 4). During this phase 
the lab results show low counts of white blood cells and platelets as well as elevated liver 
enzymes. For fatal cases, the 2-4-day terminal period is characterized by hemorrhage, hiccups, 
somnolence, delirium, and coma. Bleeding is manifested as maculopapular skin rash, petechiae, 
ecchymosis, uncontrolled bleeding from venepuncture sites, and postmortem evidence of 
visceral hemorrhagic effusions. Abortion is a common consequence of infection, and infants born 
from mothers dying of Ebola infection are fatally infected. Death in shock usually occurs 6-9 days 
after onset of clinical disease. During the EVD initial period, blood sampling shows that all sick 
individuals have circulating viral antigen. However, recent reports of EBOV and SUDV have shown 
that fatal illness is associated with high and increasing amounts of virus in the bloodstream. 
Conversely, patients who survive infection show a decrease in circulating virus with clinical 
improvement around day 7-10. In most cases, this improvement coincides with the appearance of 
EBOV-specific antibodies (Towner et al. 2004; Sanchez et al. 2004). Although EBOV disappears 
quickly from the bloodstream of recovering patients, it was isolated from seminal fluid of a few 
patients up to the 61st day after onset of illness in a laboratory acquired case. The EVD incubation 
period varies between 2 and 21 days. During EVD outbreaks, the case-fatality rate has varied from 
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outbreak to outbreak between 25 and 90% (Mahendradhata 2005), while in the current outbreak 
is around 50% (World Health Organization (WHO) 2014). 
 
 
Figure 4. Signs and symptoms of EVD. Symptoms of EVD include fever, severe headache, muscle pain, weakness, 
fatigue, diarrhea, vomiting, abdominal (stomach) pain and unexplained hemorrhage (bleeding or bruising). Symptoms 
may appear anywhere from 2 to 21 days after exposure to EBOV, but the average is 8 to 10 days. Recovery from EVD 
depends on good supportive clinical care and the patient’s immune response. People who recover from EBOV infection 
develop antibodies that last for at least 10 years. 
 
1.1.5. Pathology and pathogenesis of EVD 
Filoviruses enter the body through mucosal surfaces or skin abrasions or through the use of 
contaminated needles (Zaki & Goldsmith 1999) (Fig. 5a). The uncontrolled EBOV replication is 
important to its pathogenesis due both to its cytopathic effects and the prominent induced 
dysregulation of the host immune response. Virally-induced immune system impairment occurs 
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through a variety of mechanisms. Studies in nonhuman primates as well as guinea pigs raise the 
possibility that monocytes, macrophages and dendritic cells are early and preferred sites of viral 
replication (Connolly et al. 1999; Geisbert, Hensley, et al. 2003), though it remains possible that 
virus is present on these cells through binding to lectin receptors. It has been suggested that 
these cells act as vehicles for the transport of virus through the lymphatic system (Hensley et al. 
2002). A further viral replication and systemic spread to other organs and tissues follows (Fig. 5b). 
Infection of monocytes and macrophages leads to the release of proinflammatory cytokines and 
chemokines, including tumor necrosis factor, interleukin-1β, macrophage inflammatory protein-1α 
and reactive oxygen and nitrogen species (Feldmann et al. 1996; Bray & Geisbert 2005). The 
expression of these mediators attracts more monocytes and macrophages to the sites of 
infection and may also attract neutrophils. Although recent data suggests that they are not 
productively infected, human neutrophils treated with filovirus in vitro show rapid activation of 
triggering receptor expressed on myeloid cells-1 (TREM-1) (Mohamadzadeh et al. 2006) that 
results in the release of further inflammatory cytokines and chemokines that contribute to 
vasodilation and increased vascular permeability. In addition, infected monocytes and 
macrophages express cell surface tissue factor, which may be involved in the development of 
coagulopathies (Geisbert, Young, et al. 2003). After infection, macrophages undergo cell lysis and 
apoptosis in large numbers (Gupta et al. 2007) contributing to viral dissemination by supporting 
viral replication or by transporting virus bound to cell surface lectin binding proteins within the 
lymphatic system. Like neutrophils, monocytes and macrophages may also secrete soluble factors 
that exacerbate pathogenic manifestations of the disease (Mohamadzadeh et al. 2006). Similarly 
to monocytes and macrophages, immature dendritic cells (DCs) are EBOV ‘targets’, either by 
means of attachment of viral particles interacting with DC-expressed C-type lectin DCSIGN or by 
means of infection interacting with other DC expressed cell-surface receptors (Fig. 5c). DCs EBOV 
infected are severely compromised in critical functions: they do not become mature or activated 
and are unable to up-regulate major histocompatibility complex (MHC) molecules and thus to 
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stimulate T cells (Bosio et al. 2003; Mahanty et al. 2003). The consequences of non-functional DCs 
include a diminished ability to stimulate humoral or cell-mediated immune responses, which may 
contribute to the lack of control of viral replication. A principal determinant of the inhibitory 
effect on innate immune function is EBOV resistance to the antiviral effects of interferon (IFN), 
which is likely to be due to interruption of critical IFN response pathways by the virus itself 
(Harcourt et al. 1998; Jahrling et al. 1999; Kash et al. 2006). In addition, the expression of ISGs 
important in the type I IFN response is decreased in EBOV infected cells (Harcourt et al. 1998; 
Kash et al. 2006; Harcourt et al. 1999). Like some other viruses, EBOV encodes specific viral 
proteins that antagonize the IFN response. In particular, 2 virally encoded proteins, VP24 and 
VP35, have been shown to interfere with the IFN response induction (Basler et al. 2003; Reid et al. 
2006; Cárdenas et al. 2006). The virus-induced inhibition of the IFN pathway not only decreases 
ISGs transcription to prevent an antiviral response state, but also contributes to lower the 
number of mature and activated myeloid DCs, which in turn hinders the activation of the adaptive 
immune response. Surprisingly, patients who succumb to EBOV infection show little evidence of 
an activated adaptive immune response. Adaptive immunity is severely compromised also 
because lymphocytes undergo massive apoptosis in infected humans and nonhuman primates 
(Gupta et al. 2007; Baize et al. 1999; Reed et al. 2004). As a result, the number of CD4+ and CD8+ T 
cells is substantially reduced in fatal human and nonhuman primate infections before death (Baize 
et al. 1999; Reed et al. 2004; Sanchez et al. 2004) (Fig. 5d). The pathological changes seen in 
patients dying of EVD include coagulation abnormalities, vascular permeability, haemorrhage and 
organ necrosis and failure. The current hypothesis is that the fundamental mechanism of EBOV 
pathogenesis is vascular injury and damage secondary to coagulation abnormalities and increased 
vascular permeability, due to the release of inflammatory cytokines and chemokines by infected 
and activated monocytes and macrophages, and to direct endothelial cell damage from viral 
replication late in infection (Mahanty & Bray 2004; Mohamadzadeh et al. 2007). The direct viral 
damage of tissues and organs may lead to organ failure and shock. The infection of certain cell 
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types plays an important role in EBOV pathogenesis. Infection of innate immune cells is thought 
to be pivotal to the systemic dissemination of the virus during human infection (Geisbert, 
Hensley, et al. 2003; Connolly et al. 1999). In addition, infection and necrosis of hepatocytes cause 
impairment of liver function. Liver enzymes are elevated in most filovirus infections (Fisher-Hoch 
et al. 1992; Johnson et al. 1995; Ryabchikova et al. 1999), and decreased liver functions could 
account for the decreased synthesis of coagulation factors and development of coagulation 
disorders prominent during fatal infection. Finally, the development of shock at later stages of 
the disease is multifactorial and, along with haemorrhage, may be due in part to the infection and 
resulting necrosis of cells of the adrenal cortex that are important in the regulation of blood 
pressure (Ryabchikova et al. 1999). Although filoviruses are among the most virulent and fatal 
pathogens known, some patients infected with Ebola virus recover from the infection. In fact, it is 
evident that an early and robust, but transient, innate immune response and the subsequent 
activation of adaptive immune response are necessary to protect against fatal infection. If such a 
host immune response is not generated, the virus evades immune control and the infection 
progresses to end-stage disease (Zampieri et al. 2007). 
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Figure 5. Infection, spread and target cell destruction by Ebola virus. (a) Ebola virus (yellow) infects subjects through 
contact with body fluid or secretions from an infected patient and is distributed through the circulation. Entry can occur 
through abrasions in the skin during patient care, burial rituals and possibly contact with infected bushmeat, or across 
mucosal surfaces. Accidental needle stick is the primary route of occupational exposure. (b) Early targets of replication 
are reticuloendothelial cells, with high replication in several cell types within the lungs, liver and spleen. (c) Dendritic 
cells, macrophages and endothelium appear to be susceptible to cytopathic effects of EBOV gene products through 
disruption of cellular signaling pathways affected by virus binding, phagocytic uptake or both. Indirect damage may 
also be inflicted by circulating factors such as tumour necrosis factor and nitric oxide. (d) Virus infection and 
uncontrolled replication causes lysis of monocytes/macrophages, DCs, and hepatocytes and suppresses innate immune 
response in these cells. Direct injury to infected cells is accompanied by indirect effects mediated by pro-inflammatory 
and anti-inflammatory cytokines and chemokines. 
d 
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1.1.6. Structure of Ebola virus 
EBOV virions produced in tissue culture are pleomorphic, appearing as either U-shaped, six-
shaped, or circular (torus) configurations, or as elongates filamentous forms (Kuhn 2008). A 
typical EBOV virion contains one viral nucleocapsid (NC) that runs through a cylindrical axis of ~80 
nm in diameter and is enwrapped by an envelope acquired from the host cell membrane during 
virus budding. The average virion length is ~982 nm, with a molecular mass of about 3.82 x 105 
kDa. In addition to this common form, other viral particles are observed, such as “continuous-
virions” containing 2 NCs or more in multiples by an integer of 2, and “linked-virions” composed 
of single NCs that are connected by short sections of an empty envelope (Beniac et al. 2012). 
EBOVs NC is a tubular, ~50 nm-wide, cross-striated and double-layered helix. The inner layer is 22 
nm in diameter and consists of a 18.9 kbp ssRNA genome that is tightly associated in its entire 
length by regular repeats of the viral nucleoprotein NP, which, in turn, are connected each other 
and run along the NC axis at a pitch of ~7 nm with a periodicity of 12 subunits per helical turn 
(Bharat et al. 2012). The NP-RNA structure is then stabilized and protected by a 37 nm-wide outer 
layer, that consists of a series of “boomerang-shaped” protrusions, formed by repeats of the 
heterodimeric association between the viral minor matrix VP24 and the viral polymerase co-factor 
VP35, each one of these being bridged to different sites of two NP subunits (Bharat et al. 2012). 
Finally, in the interior of such double-layered NC, there are copies of the other viral polymerase 
co-factor VP30 and of the viral RNA-dependent RNA polymerase L protein, which are bound to NP 
and VP35 subunits, respectively. The described RNA-NP-VP24-VP35-VP30-L complex forms a loose 
soluble-layered helix that must be condensed into a rigid tubular structure to form the mature 
EBOV NC (Bharat et al. 2012). To this purpose, this helix is further surrounded by a 5 nm-wide 
lattice composed by regular repeats of the matrix protein VP40, which, associating with VP35 and 
the C-terminus of the NP subunits, provide the required stabilization to condensate the NC helix. 
Such tubular architecture is then enwrapped by an envelope originating from cellular membrane, 
in which are mounted repeats of the viral glycoprotein GP, necessary for cellular attachment and 
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fusion of EBOV virions. GPs form spikes that extend 10 nm from the envelope surface, with 3.5 nm 
stalk and 6.5 club-shaped head (Beniac et al. 2012).  These are 15 nm centre-to-centre spaced and 
have an irregular-clustered distribution on EBOV virion surface. Every spike is typically composed 
by a trimeric association of GP subunits, each one consisting of a transmembrane GP2 domain and 
GP1 mucin-like domain, the latter being the putative receptor binding domain for a cell surface 
ligand that has not yet been definitively identified (Beniac et al. 2012; Bharat et al. 2012) (Fig. 6). 
 
1.1.7. EBOV genome and proteins  
EBOVs have a linear, non-segmented, ssRNA- genome of approximately 19 kb in length and an 
average molecular mass of 4 x 103 kDa (Kuhn 2008). EBOVs genome is organized in 7 linear genes 
which encode up to 9 viral proteins, 7 of which are structural proteins found in mature virions, 
while 2 additional proteins are secreted and do not participate to the formation of viral particles 
(Fig. 7). Such organization is almost identical among the five EBOV species, very similar with that 
of the closely related filoviruses MARV and LLOV and it is also shared, among Mononegavirales, 
between Filoviridae and the other three families in the order, such as Paramixoviridae, 
Rhabdoviridae and Bornaviridae (Barrette et al. 2011). EBOV genome is not polyadenylated at its 3’ 
terminus and is uncapped at its 5’ termini. At both genomic ends there are two brief extragenic 
regions, namely leader (l) and trailer (t) regions (Fig. 7), which contain sequences of cis-acting 
signals for the genome endcapsidation, replication and transcription. These regions appear to be 
highly conserved in the Filoviridae family, slightly varying in length among EBOV species. Typically, 
l region comprehends the first 49-55 nucleotides at the 3’ termini, that immediately precedes the 
initiation transcription signal of the first gene. At the 5’ termini, t region consists of a variable 
number of nucleotides (from 25 up to 676) following the termination transcription signal of the 
last gene. The 2 untranslated l and t regions show a certain degree of self-complementarity and 
are also complementary each to other at both respective ends. Owing to this reciprocal base 
pairing, l and t regions may lead to the formation of secondary structures that are typically found 
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Figure 6. Structure of Ebolavirus virion. Ebola virions consist on filamentous-shaped particles enwrapped onto a host 
cell membrane-derived envelope with peplomers of the viral glycoprotein GP trimeric complexes. Under the envelope, 
an outer matrix layer is formed by the two VP40 and VP24 proteins shroud the viral NC. Immature NC consists on a 
ribonucleoprotein complex formed by a ssRNA (-) encapsidated by protomers of the NP and associated to the viral 
proteins VP30 and VP35-L complex, which represent the viral RNA-dependent RNA polymerase holoenzyme (Goodsell 
2014). 
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in EBOV genome ends, including the stem loop, the hairpin loop and the panhandle structure 
(Crary et al. 2003; Mühlberger 2007). The 7 EBOV genes are tandemly arranged in the following 
linear order: NP, VP35, VP40, GP, VP30, VP24 and L. The first EBOV gene codes for the NP, a 
nucleoprotein of 739 amino acid residues and a predicted molecular mass of 83.3 kDa that is as 
major component of the EBOV NC by tightly encapsidating both viral RNA genome and 
antigenome. The second gene codes for the viral protein VP35, a 340 amino acid long protein of a 
35 kDa mass which acts as a component of the replication and transcription holoenzyme and is 
also an assembly factor of EBOV viral particles. Moreover, VP35 is a determinant of EBOVs 
virulence, being an antagonist of the host antiviral innate immune response. The third gene along 
EBOV genome encodes for the viral protein VP40, a major protein consisting of 326 residues and a 
molecular weight of 35 kDa. VP40 forms the viral matrix in which EBOV NCs are assembled into 
mature virions and also plays a critical role during virus budding. The GP protein is the only EBOV 
structural glycoprotein and is encoded by the homonymous fourth gene after a process of mRNA 
editing. GP is translated as a 676 amino acid precursor and then processed by host enzyme furin 
into the two disulphide-linked heterodimer that decorates the EBOV envelope. The same, 
unedited transcript of GP gene encodes for two non-structural glycoproteins, the 291 amino acid 
residues sGP and the amino acid residues ssGP, which are secreted as soluble glycoprotein from 
infected cells. The fifth EBOV gene codes for the viral protein VP30, a 288 amino acid residues 
protein with a molecular mass of 32 kDa that acts as a component of the EBOV NC and is a 
polymerase co-factor important for EBOV transcription. The sixth gene codes for VP24, a matrix 
protein of 251 amino acid residues and a molecular weight of 28.2 kDa. The viral protein VP24 
plays a structural role in viral assembly and also in an antagonist of the host innate immune 
response to viral infection. Finally, the seventh and last gene of EBOV genome encodes for the L 
protein, a large protein of 2212 amino acids and a molecular weight of 252.7 kDa that constitutes 
the catalytic site of the EBOV RNA-dependent RNA polymerase complex. The coding region of 
each ebolaviral gene consists of a central open reading frame (ORF) with highly-conserved 
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transcription initiation and termination sequences that contain the pentameric sequence 3’-
UAAUU-5’. For 1 EBOV gene, the GP, there are 3 different ORFs in the GP gene, which code, 
through a process of mRNA editing, for 3 distinct forms of the viral glycoprotein, one of which is a 
structural (GP) and two are non-structural secreted proteins (sGP and ssGP). The ORF of each 
EBOV gene is flanked at both sides by long non-translated sequences, termed intergenic regions 
(IR), which vary in length (from 57 up to 684 bp) and nucleotide composition among EBOVs 
species and are seemingly not essential for viral transcription. EBOV genes also share overlapping 
regions (OR), that reside between VP35 and VP40 genes and between VP24 and L genes in the 
RESTV species, while EBOV, SUDV, TAFV and BDBV species possess an additional third OR 
between GP and VP30 genes (Kuhn 2008) (Fig. 7). 
 
 
Figure 7. Organization of EBOV genome. Schematic diagram of the EBOV ssRNA (-) genome with its coding regions. 
Transcription start signals are depicted as green triangles and stop signals as red bars. leader, trailer, intergenic (IR) and 
overlapping regions (OR) are indicated. 
 
1.1.8. EBOV cellular cycle 
While having a preference for monocytes, macrophages, DCs, endothelial cells and hepatocytes, 
EBOVs are pantropic in infecting multiple cell types and exploit their enzymatic machineries 
through a replication cycle that is entirely cytoplasmatic (Takada 2012). EBOVs entry into target 
cells occurs by macropinocytosis and requires attachment of EBOV GP protein to a receptor 
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molecule that has not yet been identified (Olejnik et al. 2011). In fact, none of the cellular proteins 
implicated in ebolaviral entry totally match with EBOVs tropism and it remains allusive whether 
these molecules act as functional receptors mediating both viral attachment and membrane 
fusion or are rather co-receptors required only to enhance these processes (Takada 2012). 
According to the model currently proposed (Fig. 8), trimers of GPs on EBOV virion surface interact 
with members of the C-type lectin family (such as DC-SIGN, L-SIGN and hMGL) that concentrate 
virions on permissive cells before receptor engagement. Next, viral particle is internalized into an 
endosomal vesicles, likely as a consequence of the interaction between GP and the T-cell 
immunoglobulin and mucin domain 1 (TIM-1) protein with the participation of members of the 
Tyro3/Axl/Mer (TAM) co-receptors family (Olejnik et al. 2011). Following internalization, 
acidification of the endosomal lumen triggers cellular proteases Cathepsin L and B to trim the 
EBOV GP into a smaller form that, with the cooperation of at least one as yet undetermined 
factor, elicits fusion of viral envelope with host endosomal membrane. Cleavage of GP by 
endosomal cathepsins removes heavily glycosylated regions in GP1 subunits, thereby exposing a 
region that acts as ligand for the Niemann-Pick C1 (NPC1) protein, an endosomal cholesterol 
transporter that has been found essential for filovirus infection (Takada 2012). NCP1 likely 
mediates fusion of EBOV GP2 loop into endosomal membrane, this step being followed by the 
collapse of GP into a six-helix bundle that allows for lipid mixing and hemifusion of the host and 
viral membrane lipids. The hemifused membranes finally resolve forming a pore through which 
the EBOV NC is released in the cytoplasm, allowing viral replication cycle to continue. After the 
fusion, the viral particles uncoating takes place and EBOV antigenoma is transcribed into mRNA 
using viral proteins associated with NC. The genome transcription is mediated by VP30, VP35 and 
viral polymerase L complex bound to the genome coated by NP (Hartlieb et al. 2003; Bharat et al. 
2012). VP30 phosphorylation leads to dissociation of the VP35/L complex and is the signal for the 
transition from transcription to replication process (Martinez et al. 2011; Biedenkopf et al. 2013). 
Therefore, the viral genomes are replicated and coated with NP, VP24, VP30 and VP35 
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(Muhlberger et al. 1999). During assembly, L binds to the ribonucleoprotein complex through 
interaction with VP35. Subsequently, ribonucleoproteins bind to the matrix protein VP40, which 
mediates the transport of immature viral particles up to the plasma membrane through the COPII 
transport system (Yamayoshi et al. 2008). After reaching the plasma membrane, the virion moves 
through lipid rafts, in which the final assembly takes place and through which the extrusion of 
mature viral particles occurs (Fig. 8) (Stahelin 2014). 
 
 
Figure 8. EBOV replication cycle. Attachment of the GP virion to an unidentified host surface receptor results in 
receptor-mediated macropinocytosis. The virion is acidified within the endocytic vesicle leading to the uncoating of the 
NC and release of the viral RNA genome into the cytoplasm of the host cell. Polyadenylated monocistronic mRNAs are 
synthesized from the negative-sense genomic RNA template by the replicase-transcriptase VP35-L-VP30 holoenzyme 
and translation of the viral mRNA genome yields the filoviral structural proteins. Viral replication of the positive-sense 
antigenome serves as template for the generation of the negative-sense progeny genomes. Prolonged replication 
produces excessive amounts of viral proteins, which facilitates transition from transcription/translation to replication 
within host cells. The concentration of NP is the primary trigger that induces this transition between mRNA 
transcription/translation and genomic replication. Binding of NP to progeny genomic RNA with VP35, VP30 and L result 
in the formation of immature ribonucleocapsids which, in turn, are enwrapped by VP24 and VP40 onto a matrix layer. 
Following assembly, virions are released from the host cell by budding of membrane-inserted GP peplomers.  
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1.1.9. Countermeasures against EVD 
Identify patients with symptoms consistent with the case definition as outlined by the WHO and 
the Centers for Disease Control and Prevention (CDC), is the first step of clinical management, 
especially for patients in geographical areas where EBOV infections have previously been 
reported and/or patients in other countries with similar symptoms who have travelled to these 
countries within the past 21 days. These patients need to be rapidly isolated, the patient contacts 
identified and appropriate containment and preventive measures instituted. Blood samples need 
to be immediately obtained and submitted to the nearest clinical laboratory certified to conduct 
diagnostic evaluation for EBOV (Goeijenbier et al. 2014). Currently, the treatment of EVD includes 
the administration of ‘supportive care’ and treatment strategies. EVD patients benefit most from 
managing the haemodynamics and haemostasis. It was established that fluid replacement 
therapy drastically increases the chance of survival when started in the early phase of the disease 
(Fowler et al. 2014). Ribavirin, the only known antiviral that is effective against certain VHF 
pathogens such as Lassa fever, is not effective against Ebolaviruses (Jahrling et al. 1999; Huggins 
1989). Various drugs with a potential effect in EVD are in the experimental phase and have shown 
beneficial effects against EBOVs (mainly EBOV and SUDV) in animal models and have been used in 
small numbers to treat EVD patients. The WHO declared that, considering the magnitude and 
severity of the current outbreak, it is ethical to use experimental drugs for treatment and 
prevention of EVD.  ZMapp is a cocktail of monoclonal antibodies and is being used to treat some 
victims of the current EBOV outbreak. Its role in EVD treatment still needs to be established, since 
efficacy data in humans have not been published yet. The strongest evidence that ZMapp is 
indeed effective in EVD comes from experiments in non-human primates in which ZMapp was 
able to revert advanced EVD when administered up to five days post infection (Qiu et al. 2014). 
Unfortunately, there is a limited supply of ZMapp at this moment.  Of the non-antibody based 
antiviral preparations, only the nucleoside analogue favipiravir has been tested extensively in 
humans. Recently the drug gained approval in Japan for use in humans infected with novel and re-
 
31 
 
emerging influenza viruses. Besides activity against influenza virus infection, this drug also has 
documented activity against a wide variety of RNA viruses including EBOVs (Furuta et al. 2013; 
Smither et al. 2014). Favipiravir prevented death in mice infected with EBOV when treatment was 
started six days post infection (Oestereich et al. 2014). These results are promising, but need to be 
confirmed in a non-human primate model. BCX-4430 is also a nucleoside analogue with broad 
spectrum activity against RNA viruses and has proven to be effective against the Marburg virus in 
a non-human primate model and Ebola virus in a mouse model (Warren et al. 2014). Finally, TKM-
ebola and AVI-6002 are under development for the treatment of EVD and exert their action via 
gene silencing. Both drugs have proven to be effective in mouse and primate models, and some 
safety and pharmacokinetic data in humans are available for AVI-6002 (Geisbert et al. 2010; 
Warren et al. 2010; Heald et al. 2014).  
In earlier outbreaks attention was paid to potential treatment of EVD patients with blood 
transfusion from EVD survivors. For instance, in the EVD outbreak in Kikwit (Democratic Republic 
of Congo) in 1995, patients receiving convalescent serum from EVD survivors showed a much 
lower CFR (Mupapa et al. 1999). However, these results were based on a small number of patients 
with a potential treatment bias. Furthermore, this passive immunotherapy did not seem to be 
effective in a non-human primate model (Jahrling et al. 2007). Due to the potential for antibodies 
to enhance viral infections via antibody-enhancement mechanisms, a note of caution is in 
placement for the use of passive immunotherapeutic strategies. In addition, since antivirals are 
small molecules, increasing their production to a larger scale should be easier than it would be for 
monoclonal antibodies, resulting in a more effective strategy against EVD. 
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1.2. Antiviral Innate Immune Response 
Defense mechanisms against infectious pathogens are regulated in concert with innate and 
adaptive immunity. The innate immune system, in particular, is essential to initiate these anti-
pathogen immune activities in both peripheral and lymphoid tissues. Viral infections in children 
and young adults are common and generally uneventful. In most instances, the patients recover 
and either eliminate the virus or incorporate it in a latent or persistent form without further 
problems. Although viruses are obligate intracellular parasites and rely entirely on the metabolic 
machinery of the host cell, they usually do not cause much harm. The main reason is that our body 
is not defenseless but makes use of numerous measures to keep viruses at bay. The type I IFN 
system is a major player in antiviral defense against all kinds of viruses. Virus-infected cells 
synthesize and secrete type I IFN (IFN-α/β) which warns the body of the dangerous intruders. 
Secreted IFNs circulate in the body and cause susceptible cells to express potent antiviral 
mechanisms which limit further viral growth and spread (Haller et al. 2006; Yoneyama & Fujita 
2010). 
 
1.2.1. IFN system 
IFNs are a group of secreted cytokines that elicit distinct antiviral effects. They are grouped into 
three classes called type I, II and III IFNs, according to their amino acid sequence. Type I IFNs 
(discovered in 1957; Isaacs & Lindenmann 1957) comprise a large group of molecules; mammals 
have multiple distinct IFN-α genes (13 in man), one to three IFN-β genes (one in man) and other 
genes, such as IFN-ω, -ε, -τ, -δ and -κ. The IFN-α and -β genes are induced directly in response to 
viral infection, whereas IFN-ω, -ε, -δ and -κ play less well-defined roles, such as regulators of 
maternal recognition in pregnancy (Randall & Goodbourn 2008). Type III IFNs have been 
described more recently and comprise IFN-λ1, -λ2 and -λ3, also referred to as IL-29, IL-28A and IL- 
28B, respectively (Ank et al. 2006; Uze & Monneron 2007). These cytokines are also induced in 
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direct response to viral infection and appear to use the same pathway as the IFN-α/β genes to 
sense viral infection (Onoguchi et al. 2007). Type II IFN has a single member, also called IFN-γ or 
‘immune IFN’, and is secreted by mitogenically activated T cells and natural killer (NK) cells, rather 
than in direct response to viral infection (Randall & Goodbourn 2008). IFN-α/β acts through a 
common heterodimeric receptor, which appears to be expressed ubiquitously, to activate a 
signal-transduction pathway that triggers the transcription of a diverse set of genes that, in total, 
establish an antiviral response in target cells. These genes are referred to as IFN-inducible genes 
or IFN-stimulated genes (ISGs). A subset of ISGs can also be induced directly (in an IFN-
independent manner) by viral infection, perhaps offering a degree of protection in the primary 
infected cells, although the dramatic viral sensitivity of IFN-α/β receptor-knockout mice suggests 
that this is much less effective than the IFN response itself. In addition to the cell-autonomous 
activities of IFN-α/β, these cytokines modulate the immune system by activating effector-cell 
function and promoting the development of the acquired immune response. The type I IFN 
system is indispensable for vertebrates to control viral infections. The importance of type I IFNs is 
further demonstrated in instances where disruption of a single IFN effector gene causes a 
complete loss of innate immunity against a particular type of virus, leading to overwhelming 
infection and rapid death (Haller et al. 2006). 
Before an appropriate immune response can be generated, the virus needs to be recognized. For 
this, immune cells are equipped with different groups of receptors, which are able to sense 
microbial intruders including viruses. These pattern recognition receptors (PRRs) recognize 
pathogen associated molecular patterns (PAMPs), which are fundamentally different from host 
structures (Gaajetaan et al. 2012). However, major viral PAMPs are viral nucleic acids, which are 
structurally similar to the host’s; therefore, the process by which PRRs distinguish self from non-
self nucleic acids has to be strictly regulated. Three PRR families have been identified as nucleic 
acid-sensing PRRs; endosomal Toll-like receptors (TLRs), cytoplasmic retinoic acid inducible gene 
(RIG-I)-like receptors (RLRs) and uncharacterised DNA sensor molecules. These PRRs commonly 
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activate type I IFNs in addition to pro-inflammatory cytokines. TLRs are transmembrane 
receptors, which detect PAMPs on the outer membrane or in the endosomal compartment 
(Kawai & Akira 2007). On the other hand, RLRs are involved in the recognition of cytoplasmic 
PAMPs (Takeuchi & Akira 2008). Viral nucleic acids are specifically recognised by endosomal TLRs, 
RLRs and DNA sensors. Taken together, the innate immune system is equipped with a large 
variety of PRRs and this extended array is essential to sense the various microbial components 
and to prevent or limit viral spread as much as possible (Yoneyama & Fujita 2010). 
 
1.2.1.1. RIG-I-like Receptors (RLRs) 
RLRs, DExD/H-box-containing RNA helicases, are sensor molecules for the detection of viral RNA 
in the cytoplasm of infected cells. RLR genes are found only in the genome of higher vertebrates, 
therefore it is believed that RLRs have evolved as specialised receptors for the type I IFN system 
(Sarkar et al. 2008). In mammals, three family members have been identified, retinoic acid 
inducible gene I (RIG-I), melanoma differentiation associated gene 5 (MDA5) and laboratory of 
genetics and physiology 2 (LGP2) (Yoneyama & Fujita 2009). All three RLRs contain a typical RNA 
helicase domain with RNA-dependent ATPase activity. In the N-terminal portion of RIG-I and 
MDA5, two caspase recruitment domains (CARDs) are encoded; however LGP2 is completely 
devoid of CARDs. Since the CARD of RLR is implicated in the activation of downstream signalling 
via homotypic interaction with a CARD-containing adaptor molecule, mitochondrial antiviral 
signalling (MAVS) (also known as, IFN-promoter stimulator 1 (IPS-1), virus-induced signalling 
adaptor (VISA), and CARD adaptor inducing IFN (Cardif)) (Seth et al. 2005), both RIG-I and MDA5 
are positive regulators in antiviral innate immunity. On the other hand, the function of the CARD-
less LGP2 remains unclear. Another functional domain of RLRs is the C-terminal domain (CTD), 
also termed the repressor domain (RD). The CTD/RD of RIG-I and LGP2 is known to have dual 
functions; repression of RIG-I activity in the absence of a viral infection and recognition of specific 
viral RNA after an infection. The expression profile of RLR contrasts strikingly with that of TLRs. 
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RLRs are exclusively expressed in the cytoplasm, therefore RLRs detect viral RNA inside of the 
cytosol (Yoneyama et al. 2004). Moreover, since RLRs are ubiquitously expressed in most cell 
types, they are responsible for the eradication of viruses via the innate antiviral activity of IFNs. All 
three RLRs are typical ISGs, therefore positive feedback regulation of the signalling is provoked 
after a viral infection (Fig. 9) (Yoneyama & Fujita 2010). 
 
 
Figure 9. Activation of the type I IFN antiviral response triggered by the RLRs pathway upon dsRNA detection. Viral 
short 5’-ppp dsRNA and long dsRNA are preferentially recognized by the CTD of RIG-I (violet) and of MDA5 (azure) 
respectively, with LGP2 modulating the activity of RIG-I helicase. Upon dsRNA binding to their Hel domain (green), ATP-
mediated homo-oligomerization, translocation onto dsRNA, ubiquitination, and TRIM25- or Riplet-mediated 
ubiquitination, RLRs interact through their CARDs (orange) with the CARD of mitochondrion-associated MAVS (red). 
Signaling prosecution involves recruitment of TRAF3, NEMO and STING adaptors and the assembly of TBK1- IKK-ε 
complex, which phosphorylates IRFs. Activated IRF dimers translocate to the nucleus and, together with other 
transcription factors, induce the expression of IFN-α/β. Type I IFNs are secreted and bind to their cognate receptor, 
activating STAT transcription factors for the induction of several ISG products with antiviral activity and the 
overexpression of RLRs pathway components (Zinzula & Tramontano 2013). 
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RIG-I. RIG-I is a key sensor of RNA virus infections and activator of the signaling cascade leading to 
production of type I IFN. Through a number of studies, RIG-I has been demonstrated to be the 
main recognition receptor for multiple RNA viruses including Newcastle disease virus (NDV), 
vesicular stomatitis virus (VSV), Sendai Virus, HCV, Japanese encephalitis virus (JEV), influenza A 
virus, rabies virus, measles virus, and respiratory syncytial virus (RSV) (Foy et al. 2005; Kato et al. 
2005; Melchjorsen et al. 2005; Hornung et al. 2006; Liu et al. 2007). RIG-I mediated signaling 
cascade leads to activation of IRF-3 and NF-κB (Yoneyama et al. 2004). The critical adaptor for 
RIG-I signaling was identified as a mitochondrially located, CARD containing protein, MAVS. This 
adaptor is activated via CARD-CARD association with RIG-I and initiates a signaling cascade 
leading to activation of IFN-β transcription factors and subsequent production of IFN (Seth et al. 
2005). RIG-I preferentially binds to short (<300 bp) ssRNAs and dsRNAs that have blunt ends and 
a 5’ triphosphate (5’-ppp) (Reikine et al. 2014). Since RIG-I-dependent viruses expose a 5’-ppp 
signature in the process of viral entry or replication, the RNA genome of these viruses is 
recognised by RIG-I. This specificity also explains the strict discrimination between self and non-
self RNA by RIG-I, because most endogenous RNAs lose their 5’-ppp group in the process of 
maturation, and escape detection by RIG-I (Yoneyama & Fujita 2010). RIG-I can be divided into 
three basic domains, the N-terminal CARD, central helicase domain, and C-terminal regulatory 
domain (Fig. 10). The N-terminal tandem CARD domains are required for interaction with the 
MAVS CARD domain and downstream signaling. The carboxy-terminal CTD/RD of RIG-I has proven 
to contain multiple diverse functions critical to RIG-I activity. Through mutational analysis, this 
domain was identified to possess the repressor activity responsible for self-inhibition. The 
repression of signaling likely occurs through intramolecular association between the CTD/RD and 
both the CARD and helicase domains (Takahasi et al. 2008). A conformational change induced by 
RNA binding leads to the unfolding of the molecule and exposure of the CARD allowing for 
downstream signaling. In addition to signaling repression and RNA recognition, the CTD/RD 
domain has also been characterized as being required for RIG-I dimerization. The exact role of the 
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helicase domain in RIG-I activity has been the most challenging to elucidate. The biochemical roles 
of this domain can be separated into two related but separate enzymatic functions, ATPase 
activity and helicase/translocase activity. The helicase domain also appears to have an important 
role in RNA binding (Baum & García-Sastre 2010). Formation of the RIG-I-MAVS complex on 
mitochondria induces the assembly of protein complexes to initiate downstream signalling. As 
signalling molecules, TRAF3/6, caspase-8/10, RIP1, Fas-associated death domain (FADD) and TNF 
receptor-associated death domain (TRADD) were demonstrated to be involved in the signalling. 
These molecules induce kinase activities of both IKKα/IKKβ and TBK1/IKK-ε complexes to activate 
NF-κB and IRF-3, respectively, leading to the production of proinflammatory cytokines and type I 
IFNs. Several ubiquitinating or deubiquitinating enzymes have been identified as regulators for 
RIG-I and related signalling molecules, as Tripartite motif protein (TRIM) 25, which is an E3 
ubiquitin ligase and specifically interacts with RIG-I CARD and conjugates Lys-63-linked ubiquitins, 
which are required for interaction between RIG-I and MAVS (Yoneyama & Fujita 2010).  
MDA5. MDA5 was identified as a DExD/H helicase family member during a screening of genes, 
which were upregulated by IFN treatment and at the same time involved in growth suppression 
of melanoma cells. Similar to RIG-I, MDA5 contains two N-terminal CARD domains, a dsRNA-
dependent ATPase motif within a central helicase domain, and a regulatory C terminal domain 
(Fig. 10) (Kang et al. 2002). In contrast to RIG-I, MDA5 preferentially binds internally to long 
dsRNA (> 1000 bp) with no end specificity and cooperatively assembles into a filament on the 
dsRNA. Unlike RIG-I, the CARDs of MDA5 are not sequestered in the absence of ligand. The forced 
proximity of the CARDs upon MDA5 filament formation induces oligomerization of MDA5 CARDs, 
forming a scaffold for binding and oligomerization of MAVS CARD. Notably, the atomic structures 
of the MDA5 CARDs have not yet been determined. A crystal structure of the MDA5 helicase 
domains and CTD/RD bound to dsRNA revealed how MDA5, despite having a similar domain 
architecture as RIG-I, recognizes dsRNA in a different manner. The helicase domains of MDA5 
wrap around dsRNA similarly to the helicase domains of RIG-I. However, consistent with the 
 
38 
 
observation that MDA5 is not preferentially activated by 5’-ppp dsRNA (Kato et al. 2006), the 
MDA5 CTD/RD is rotated by 20°, bringing it closer to the dsRNA, as compared to the RIG-I 
structure. This orientation of the CTD promotes cooperative filament formation along dsRNA, 
initiated from internal sites in the dsRNA rather than from one of the ends (Berke & Modis 2012). 
The molecular machinery of MDA5-mediated signal transduction is known to be almost identical 
to the one of RIG-I-mediated signal transduction. However, a MDA5-specific negative regulator, 
dihydroacetone kinase (DAK) has been identified (Diao et al. 2007). DAK associates with MDA5, 
but not RIG-I, and inhibits polyI:C-induced IFN production. Further analysis will be necessary to 
determine the physiological function of MDA5 in the regulation of adaptive immunity. 
LGP2. The third member of the RLR family, LGP2, has been implicated as a negative regulator of 
RIG-I and a positive regulator of MDA5; however, the exact role of this molecule in viral infection 
remains controversial. Like RIG-I and MDA5, LGP2 contains a DExH/D box helicase domain and a 
carboxy-terminal CTD/RD (Fig. 10). However, unlike those receptors, it lacks the CARD domain, 
and therefore, it is unable to signal through MAVS. Since LGP2 recognises RIG-I ligands, such as 
short dsRNA, with greater affinity than RIG-I, the sequestration of RNA from RIG-I could be the 
reason for the inhibitory effect of LGP2. Since LGP2 CTD can function as RD (Saito et al. 2007), it 
may directly interact with RIG-I and inhibit its activation. Alternatively, it has been shown that 
LGP2 can interact directly with MAVS and competes in the binding between MAVS and IKKε, 
leading to inhibition of RIG-I-mediated signalling (Komuro & Horvath 2006). On the other hand, 
analyses of LGP2 knockout mice indicated that LGP2 positively regulates EMCV-induced antiviral 
activity. Although the precise molecular mechanism of this positive effect of LGP2 has been 
uncharacterised, one possible explanation is the cooperative recognition of viral dsRNA with 
MDA5. Further analysis will be necessary to address this issue (Yoneyama & Fujita 2010). 
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Figure 10. RLR domains and their function. The RLR proteins can be divided into three basic domains. (1) The N-terminal 
CARD domain, composed of two tandem CARDs. (2) The central helicase domain, belonging to the DExD/H family of 
RNA helicases. (3) The unique C-terminal domain containing multiple regulatory functions (RD). The CARD domain, 
present in RIG-I and MDA5 but absent in LGP2, is required for interaction with MAVS and downstream signaling. CARD1 
(C1) is involved in physical interaction with the CARD domain of MAVS, whereas CARD2 (C2) of RIG-I undergoes 
ubiquitination required for RIG-I activation. The helicase domain contains six conserved DExD/H helicase motifs and is 
involved in translocation/unwinding of RNA and ATP hydrolysis required for RLR function. The helicase domain is also 
implicated in RNA binding for all three RLR members. The RD is required for recognition and binding of RNA substrates. 
This domain provides specificity for either 5’-ppp containing RNA (RIG-I) or dsRNA (MDA5, LGP2). RD is also required for 
homo- (RIG-I, MDA5) and hetero- (LGP2) dimer formation, necessary for signaling by these receptors. The RD of RIG-I 
additionally provides a unique function of auto-repression, and RIG-I constructs lacking the RD domain constitutively 
induce IFN in the absence of RNA stimuli (Baum & García-Sastre 2010). *Activity has not been shown directly and is 
assumed based on sequence similarity to the helicase domain of RIG-I. 
 
1.2.1.2. Toll-like Receptors (TLRs) 
TLRs are a family of single-transmembrane proteins expressed predominantly in immune cells, 
such as macrophages and DCs (Kawai & Akira 2007). Characteristic features of TLRs are the 
extracellular leucine-rich repeat (LRR), which is involved in the recognition of specific PAMPs, and 
an intracellular signal-transduction domain known as the Toll/IL-1 receptor (TIR) domain. Among 
the TLR family members, TLR1, 2, 4, 5 and 6 are expressed on the cell surface and responsible for 
the detection of bacterial and fungal cell wall components as PAMPs, whereas TLR3, 7, 8 and 9 
recognise viral nucleic acids in the endosomal compartment. The signal transmitted through 
these TLRs commonly induces the production of proinflammatory cytokines, such as IL-6 and 
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tumour necrosis factor (TNF)-α, via the activation of NF-κB; however, the endosomal TLRs 
specifically activate type I IFNs in addition to proinflammatory cytokines. These endosomal TLRs 
commonly require an endoplasmic reticulum protein, UNC-93B, which is responsible for delivering 
them to the endosomal compartment (Kim et al. 2008). 
TLR3. TLR3 detects dsRNA, which is found in the genome of dsRNA viruses or replication- or 
transcription- intermediates of ssRNA of RNA or DNA viruses (Fig. 11a). Expression of TLR3 is 
predominantly observed in the intracellular compartments of cDCs and macrophages, while some 
fibroblasts also express TLR3 on their cell surface. A dsRNA ligand is recognised by TLR3 via its N-
terminal ectodomain (ECD), which consists of an N-terminal-specific LRR (LRR-NT), 23 LRRs, and a 
C-terminal-specific LRR (LRR-CT). TLRs are known to utilise specific adaptor molecules to transmit 
downstream signalling. In the case of TLR3, the essential adaptor is TIR domain-containing 
adaptor inducing IFN-β (TRIF) (also known as TIR domain-containing adaptor molecule 1 
(TICAM1)). TRIF directly interacts with TLR3 via TIR-TIR homotypic interaction and recruits a set of 
signalling molecules, including TNF receptor-associated factors (TRAF)3, TRAF6, receptor 
interacting protein 1 (RIP1), and transforming growth factor-alpha activated kinase 1 (TAK1), 
leading to the activation of transcription factors NF-κB, IRF-3 and IRF-7. 
TLR7/TLR8. TLR7 and TLR8 are structurally homologous and are sensors of ssRNA. In the human 
system, TLR7 is predominantly expressed in pDCs and involved in the robust expression of IFN-α, 
whereas the expression of TLR8 is observed in myeloid DCs and monocytes. Since both TLR7 and 
TLR8 are expressed in the intracellular endosomal compartment, the endosomal degradation of 
viral particles to expose viral ssRNA is required for the recognition by TLR7/8. TLR7/8 transmits 
signals via a specific adaptor molecule, MyD88, which contains a TIR domain and a death domain. 
Upon the binding of a ligand, the TIR domain of TLR7/8 interacts with MyD88, and recruits 
downstream signalling molecules, IRAK1/2/4, TRAF3/6 and Osteopontin. IRF-7, which is 
constitutively expressed in pDCs, is recruited to this signalling complex, and directly activated by 
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IRAK1 via phosphorylation at specific C-terminal serine residues (Fig. 11b) (Yoneyama & Fujita 
2010). 
TLR9. TLR9 is predominantly expressed in the endosomal compartment of pDCs and B cells, and 
implicated in the detection of CpG-containing DNA. TLR-9-mediated signalling, which leads to the 
production of both proinflammatory cytokines and IFN-α, is almost identical to the TLR7/8 
pathway (Fig. 11b) (Yoneyama & Fujita 2010). 
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a  
b  
Figure 11. TLR3-, TLR7- and TLR9-dependent signalling. (a) dsRNA binds to TLR3. Activated TLR3 recruits the adaptor 
TRIF that, in turn, acts as a scaffold to recruit signalling components that feed into either the IRF-3 or the NF-κB 
pathways. NF-κB activation requires TRAF6 and RIP1 recruitment to TRIF and their co-operation in recruiting the IKK 
complex and TAK1. TAK1 phosphorylates the IKKβ subunit of the IKK complex, leading to its activation and 
phosphorylation of IκB. Phosphorylated IκB is ubiquitinated and subsequently degraded by proteasomes, releasing NF-
κB for migration to the nucleus (green arrow) and assembly on the IFN-β promoter. IRF-3 activation requires 
recruitment of TRAF3 to TRIF. TRAF3 binds to TANK, which then binds to TBK-1 and/or IKKε, which are activated in an 
uncharacterized manner and can phosphorylate IRF-3 directly. IRF-7 is activated by TBK-1 and IKKε in a similar manner. 
The activated IRFs also migrate to the nucleus (green arrows) and assemble on the IFN-β promoter with NF-κB and ATF-
2/c-jun, leading to the recruitment of co-factors such as CBP/p300 and RNA polymerase II and, ultimately, stimulation of 
transcription. (b) ssRNA or CpG DNA bind to TLR7 or TLR9. Activated TLRs recruit the adaptor MyD88 that recruits 
IRAK-4 and IRAK-1. This complex acts as a scaffold to recruit signalling components that feed into either the IRF-7 or NF-
κB pathways. IRF-7 recruitment to the MyD88 adaptor complex requires polyubiquitination by TRAF6 in a RIP1-
dependent manner. IRF-7 is phosphorylated by IRAK-1 and a complex containing IRF-7, MyD88, TRAF6, IRAK-1 and 
possibly IRAK-4 is released and migrates to the nucleus (green arrows). Here, it assembles on the IFN-β promoter with 
NF-κB and other factors, leading to the stimulation of transcription.  
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1.2.2. Signalling responses to type I IFN 
The basic signalling pathway activated in response to IFN α/β has been characterized in detail 
(Platanias 2005) (Fig. 12). IFN-β and the multiple IFN-α subspecies activate a common type I IFN 
receptor (IFNAR) which sends a signal to the nucleus through the JAK-STAT pathway. The STAT 
proteins are latent cytoplasmic transcription factors which become phosphorylated by the Janus 
kinases JAK-1 and TYK-2. Phosphorylated STAT-1 and STAT-2 recruit a third factor, IRF-9, to form a 
complex known as IFN-stimulated gene factor 3 (ISGF-3) which translocates to the nucleus and 
binds to the IFN-stimulated response element (ISRE) in the promoter region of ISGs. Specialized 
proteins serve as negative regulators and inhibitors of the JAK-STAT pathway. The suppressor of 
cytokine signaling (SOCS) proteins prevents STAT activation (Kubo et al. 2003) whereas protein 
inhibitor of activated STAT (PIAS) family members function as small ubiquitin-like modifier 
(SUMO) E3 ligases and inhibit the transcriptional activity of STATs (Shuai & Liu 2005). Type I IFNs 
activate the expression of several hundred ISGs some of which code for antiviral proteins. To 
date, three antiviral pathways have been firmly established. These comprise the protein kinase R 
(PKR) (Williams 1999), the 2’-5’ OAS/RNase L system (Silverman 1994) and the Mx proteins (Haller 
& Kochs 2002; Haller et al. 2006).  
Protein kinase R (PKR). PKR is synthesized in inactive form and, in response to the dsRNA, 
produced during viral replication, undergoes dimerization and activation. In addition to activation 
by dsRNA, PKR is activated by protein kinase R (PKR)-activating protein (PACT) (Patel et al. 2000). 
The best-characterized substrate for PKR is the α subunit of the eukaryotic translational initiation 
factor 2 (eIF2α). Phosphorylation by PKR prevents recycling of eIF2α such that initiation is halted. 
Additionally, eIF2α phosphorylation can activate autophagy, by which the contents of a cell can 
be degraded and, for HSV-1, this limits viral replication (Talloczy et al. 2006). The involvement of 
PKR has been invoked in a number of other antiviral mechanisms, including the induction of 
apoptosis and cell-cycle arrest (Randall & Goodbourn 2008). 
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2’5’ OAS. 2’, 5' Oligoadenylate synthetase was discovered and characterized as an enzyme that in 
the presence of dsRNA converts ATP into 2'5'-linked oligomers of adenosine that  bind to and 
activate RNase L, which degrades cellular and viral RNAs. The OAS/RNase L system has been 
linked to the induction of IFN and may also affect apoptosis (Silverman 1994). 
Mx. Mx and the Mx family of genes encode large GTPases related to dynamin; the precise 
functions of Mx and the superfamily of GTPases are unknown, but they show antiviral activity 
against a wide range of RNA viruses. The Mx proteins act by recognizing nucleocapsid-like 
structures and restricting their localization within the cell, thereby restricting virus replication. For 
example, human MxA recognizes the viral nucleoprotein of Thogoto virus (THOV) and prevents 
transport of the incoming viral nucleocapsids into the nucleus (Weber et al. 2000; Randall & 
Goodbourn 2008). 
 
Figure 12. Signalling pathway activated by IFN-α/β. The biological activities of IFN-α/β are initiated by binding to the 
type I IFN receptor. This leads to the activation of the receptor associated tyrosine kinases JAK1 and Tyk2, which 
phosphorylate STAT1 on tyrosine 701 and STAT2 on tyrosine 690. Phosphorylated STAT1 and STAT2 interact strongly 
with each other by recognizing SH2 domains, and the stable STAT1–STAT2 heterodimer is translocated into the nucleus, 
where it interacts with the DNA-binding protein IRF-9. The IRF-9-STAT1-STAT2 heterotrimer is called ISGF3 and it binds 
to a sequence motif (ISRE) in target promoters and brings about transcriptional activation. In addition to the 
phosphorylation of tyrosine, STAT1 also requires phosphorylation on serine 727 for function. 
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1.3. Inhibition of Innate Immune Response 
Because of the strong antiviral and immunoregulatory role of type I IFN, viruses developed a large 
variety of anti-type I IFN mechanisms. Consequently, nearly all steps of the type I IFN pathway can 
be blocked or manipulated by different viruses for their own benefit. There are five main ways by 
which viruses circumvent the IFN response, such as i) interfering globally with host cell gene 
expression and/or protein synthesis, ii) minimizing IFN induction by limiting the production of viral 
PAMPs and/or by specifically blocking IFN-induction cascades, iii) inhibiting IFN signalling, iv) 
blocking the action of IFN-induced enzymes with antiviral activity and v) having a replication 
strategy that is (largely) insensitive to the action of IFN. Within each of these strategies, different 
viruses have evolved a great diversity of molecular mechanisms to achieve similar ends. Since 
RNA viruses tend to accumulate nucleic acid intermediates and byproducts in the host cytoplasm 
during their replication cycle, preventing recognition by host PRRs of such PAMPs is of crucial 
importance. Therefore, most RNA viruses encode proteins that display IFN-antagonism properties 
aimed to circumvent the host innate immune system. Among those proteins, most have been 
revealed as involved in targeting the RLR pathway at several levels (Versteeg & García-Sastre 
2010). The impact of this counteraction becomes particularly evident for those RNA viruses that 
cause severe diseases in humans, since in several cases the fatal outcome has been related to 
their ability to subvert the type I IFN-mediated innate immune response (Bray 2005). It is 
therefore not surprising that, among the different viral proteins identified as inhibitors of IFN-α/β 
production and signaling, most are also molecular determinants of virulence and pathogenesis 
(Bowie & Unterholzner 2008; Versteeg & García-Sastre 2010). To this category belongs EBOV, 
whose extreme lethality is the result of uncontrolled viral replication associated with a total 
impairment of the innate immune system, related, at least in part, to the properties displayed by 
three determinants of virulence and pathogenicity: VP24, VP35 and VP40 proteins. However, only 
the multifunctional polymerase cofactor VP35 acts by suppressing IFN-α/β production, while VP24 
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and VP40 matrix proteins are involved in inhibiting the type I IFN signaling pathway (Basler & 
Amarasinghe 2009; Ramanan et al. 2011). Within RNA viruses also human infections by highly 
pathogenic Influenzaviruses (IAVs) may typically result in acute respiratory distress syndrome 
with fatal pneumonia, due, at least in part, to the ability of IAVs to efficiently suppress the host 
innate immune response (Ramos & Fernandez-Sesma 2012). In particular, regarding interference 
with the dsRNA-induced production of IFN-α/β, IAVs exert their antagonism through the 
properties of at least three proteins, namely NS1, PB2 and PB1-F2, which target the RLR pathway 
at several levels and with different mechanisms. Particularly, NS1 plays a central role in virus 
replication and block of the host innate immune response through several distinct molecular 
mechanisms that are triggered by interactions with dsRNA or specific cellular proteins (Benjamin 
G. Hale et al. 2008; Ehrhardt et al. 2010). VP35 and NS1 proteins, that present similar structure and 
a IFN-antagonist function that targets the RLR pathway, are presented here in detail (Fig. 13) 
(Zinzula & Tramontano 2013). 
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Figure 13. RLRs pathway inhibition by VP35 and NS1 proteins. VP35 and NS1 inhibit the RIG-I pathway-mediated 
production of IFN-α/β. VP35 acts upstream by sequestering dsRNA to RIG-I recognition and downstream by interacting 
with the IRF-3 kinases IKK-ε and TBK-1. This prevents efficient phosphorylation of IRF-3, blocking activation of the IFN-β 
promoter. NS1 hides dsRNA to RIG-I recognition and interact directly with TRIM25 inhibiting RIG-I 
ubiquitination/activation preventing the IFN synthesis. NS1 also blocks cellular pre-mRNAs processing and prevents 
their nuclear export, including IFN mRNAs synthesized in response to viral infection. Moreover it sequesters viral 
dsRNAs from detection by 2’-5’ OAS and inhibits the activity of PKR. 
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1.3.1. EBOV VP35 protein  
In EBOV infections, recognition of viral RNA by the cytoplasmic PRR RIG-I is prevented through 
the dsRNA binding properties of the EBOV VP35 that mimics 5’-ppp dsRNA ends recognition 
performed by RIG-I (Schlee et al. 2009). EBOV VP35 also interferes with the activation of IRF-3 
(Hartman, Bird, et al. 2008) and inhibits PACT-induced RIG-I ATPase activity preventing PACT 
interaction with and activation of RIG-I (Luthra et al. 2013), allowing EBOV to evade innate 
immunity activation. As stated before, the multifunctional viral protein VP35 is also an essential 
component of the viral RNA polymerase complex and a nucleocapsid assembly factor (Basler et 
al. 2000; Basler et al. 2003; Cárdenas et al. 2006; Daisy W. Leung et al. 2010; Prins, Binning, et al. 
2010; Ramanan et al. 2012), and is critical for RNA silencing suppression (Haasnoot et al. 2007) and 
PKR inhibition (Schümann et al. 2009). These features highlight the viability of VP35 as an 
important target for therapeutic development. 
 
1.3.1.1. EBOV VP35: the gene and the protein 
Among the nine viral products encoded by the EBOV genome, the multifunctional VP35 protein is 
a key determinant of virulence and pathogenesis, which plays critical roles in several steps of the 
EBOV lifecycle, including genome replication and transcription, NC assembly and inhibition of the 
innate immune response to viral infection (Basler & Amarasinghe 2009). The VP35 protein is the 
product of a homonymous gene of ~ 1000 nucleotides in length whose locus represents the 
second ORF in the EBOV genome, located between the NP and VP40 genes (Fig. 14a). This ORF 
encodes for a protein that in Zaire subtype is 340 amino acid residues long (329 residues in SUDV 
and RESTV, 341 in TAFV and BDBV) with a molecular mass of ~ 35 kDa, from which the name. The 
amino acid sequence of VP35 consists of at least two domains (Fig. 14b). The N-terminal region is 
essential for replication and transcription of the EBOV genome. Spanning the first 220 residues, 
this region is composed of two flexible and disordered regions that flank a putative coiled-coil 
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domain (CCD) required for VP35 homo-oligomerization. This process leads to the formation of 
presumed homo-trimers and/or tetramers and was demonstrated to be indispensable for the role 
of VP35 as a polymerase co-factor (Moller et al. 2005). The C-terminal domain is instead important 
for the capability of VP35 to suppress the host innate immune response, and, given that this 
domain alone was found sufficient to exert such property, the tentative name of interferon 
inhibitory domain (IID) was proposed for it (Leung et al. 2009). Encompassing the last 120 C-
terminal residues the IID is the only one portion of VP35 that has been structurally solved so far 
(Leung et al. 2009) (Fig. 14c). VP35 IID estimated molecular mass is ~ 16 kDa and it appears as a 
monomer in solution. It is further divided into two independently folded units, an N-terminal α-
helical subdomain and a C-terminal β-sheet subdomain, connected one to the other by a short, 
flexible, 10 residues-long linker region. The α-helical subdomain is a bundle of four α-helices 
spanning residues 221-283, arranged in two layers that pack against the C-terminal β-sheet. This 
second subdomain comprises residues 294-340 and is folded into four stranded β-sheet and a 
brief, fifth α-helix (Leung et al. 2009) (Fig. 14d). Overall, the VP35 IID reveals a high degree of 
sequence similarity among filoviruses, with the most conserved residues belonging to two 
distinct basic patches, namely the first basic patch (FBP) and the central basic patch (CBP). The 
CBP is located at the very C-terminus, encompassing amino acids 304-340 and has been found 
essential for binding of VP35 to dsRNA, a property of the protein that is strongly correlated with 
its innate immune antagonism. This feature led to term VP35 IID also as RNA binding domain 
(RBD) and to consider it as a novel, unique fold that does not follow the α-β-β-β-α organization 
observed for canonical RBDs. Notably, a stretch of amino acid residues (304-313) within the CBP 
shares a very high degree of sequence similarity with the RBD of the multifunctional IAV NS1 
protein, which is a dsRNA binding protein and known antagonist of the innate immune system 
(Kimberlin et al. 2010). EBOV replication and transcription are primer-independent processes and 
synthesis of viral RNA during these phases starts with a single nucleoside triphosphate, resulting 
in production of genomes, antigenomes and viral transcripts that bear 5’-ppp ends (Hastie et al. 
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2012). Given that this feature might be a potent inducer for RLRs-mediated IFN-α/β response, viral 
mRNAs are capped shortly after their initiation, while 5’-ppp motifs in genomes and antigenomes 
are immediately and tightly bound by NP-protein protomers. Also, such encapsidation of EBOV 
genomes and antigenomes within NC has the effect to avoid annealing of template and de novo 
synthesized viral RNAs into dsRNA, which is a major ligand of RLRs (Gerlier & Lyles 2011). 
However, even though EBOV RNAs are unlikely to be found naked in infected cells, the RNA-
dependent RNA polymerase machinery is not perfect and might produce a variety of defective 
interfering (DI) RNA particles, such as read-through transcripts that remain uncapped or abortive 
genomes, antigenomes and small non-coding RNAs that fail to be encapsidated. These may 
undergo self-hybridization to form secondary structures or could anneal to complementary 
sequence resulting in dsRNA with blunt ends or exposed 5’-ppp, thus representing perfect 
agonist for the RIG-I pathway (Gerlier & Lyles 2011). To mask such DI particles and prevent 
recognition of EBOVs nucleic acids by RLRs, VP35 protein binds dsRNA in a sequence-independent 
manner, wrapping about its blunt or 5’-ppp-exposing ends (Hastie et al. 2012). As revealed by the 
two solved structures of Zaire EBOV IID in complex with 8 bp dsRNA (Daisy W Leung et al. 2010) 
and RESTV IID bound to a 18 bp dsRNA (Kimberlin et al. 2010), VP35 uses a bimodal strategy in 
which one VP35 monomer binds terminal nucleotides and the RNA phosphate backbone, while a 
second monomer binds only the phosphate backbone of dsRNA. These two modalities, termed as 
“end-capping” and “backbone-capping” respectively, lead the two VP35 monomers to assemble 
into an asymmetric dimer that creates a continuous, positively charged pocket for receiving 
dsRNA (Kimberlin et al. 2010) (Fig. 14e). The end-capping VP35 packs against the terminal bases of 
dsRNA with a non-polar face of hydrophobic residues as well as by a hydrogen bond from the 
carboxyl group of the very C-terminal I340 and, at the same time, it binds to the dsRNA phosphate 
backbone with basic residues K282, R312 and R322, which all lie within the highly conserved CBP of 
VP35 RBD. By contrast, two of those CBP residues (R312 and R322) and a third one (K339) do not 
bind dsRNA in the backbone-binding VP35, but rather form the dimer interface with the end-
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capping VP35, while residues I340, S272, R305 and Q274 are among those that make hydrogen 
bonds with the dsRNA backbone in this VP35 monomer (Daisy W Leung et al. 2010). Notably, 
amino acid residues involved in both dsRNA and dimer-interface interaction, such as R312, R322 
and K339 are those that were previously found as critical for EBOV immune suppression and VP35 
dsRNA binding (Hartman et al. 2004; Cárdenas et al. 2006; Leung et al. 2009). However, such 
unique bimodal strategy adopted by VP35 seems to efficiently compete with RLRs by exactly 
mimicking their way to approach and bind to dsRNA. Therefore, by binding and sequestering key 
recognition motifs on dsRNA, VP35 blocks recognition and signaling by RIG-I and MDA-5 and 
prevents initiation of the type I IFN innate immune response (Kimberlin et al. 2010; Daisy W Leung 
et al. 2010). 
 
1.3.1.2. EBOV VP35 function as antagonist of the innate immune system 
The multifunctional VP35 protein has been implicated in a variety of molecular mechanisms by 
which EBOVs counteract the type I IFN antiviral response (Basler & Amarasinghe 2009). According 
to the current knowledge, EBOVs strategies seem to mainly consist in targeting RLRs pathways. 
The first indication that the VP35 protein could antagonize the host IFN response came from the 
discovery that this protein was able to functionally complement the impaired growth of delNS1 
Influenza virus, a mutant virus lacking the gene that codes for the IFN antagonist NS1 protein 
(Basler et al. 2000). Follow-up experiments also demonstrated that VP35 abolishes the 
phosphorylation, dimerization and nuclear translocation of IRF-3, thereby connoting the IFN 
antagonism of VP35 in the suppression of the signaling pathway that originates from the 
activation of RIG-I upon stimulation by non self RNA (Basler et al. 2003). The search for a 
functional domain responsible of the inhibition of IRF-3 activation led to identify a dsRNA binding 
domain in the C-terminal half of VP35 that was sufficient, alone, to exert its anti-IFN properties 
(Hartman et al. 2004; Cárdenas et al. 2006). Notably, sequence alignment revealed that this 
domain of VP35 has high degree of similarity with N-terminal dsRNA binding domain of the IAV  
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Figure 14. EBOV VP35 protein. Encoded by the second ORF within the EBOV genome (a), VP35 is a multifunctional 
protein of 340 amino acid residues and a molecular weight of ~ 35 kDa (b) consisting on an unsolved N-terminal region 
with a coiled-coil domain (CCD) essential for its homo-oligomerization and replicative function, and a structurally solved 
C-terminal region that is essential for its anti-IFN properties (c). Consisting of two alpha-helical and beta-sheet 
subdomains, this interferon inhibitory domain (IID) also contains a dsRNA binding domain (d) whose core sequence, 
named as central basic patch (CBP), is highly conserved among all ebolaviral species and displays a high degree of 
identity with the dsRNA binding domain if the influenza virus NS1 protein, a known IFN-antagonist. (e) VP35 binds to 
blunt-ended or 5’-ppp dsRNA with a bimodal strategy consisting of a monomer binding the nucleic acid phosphate 
backbone (backbone binding strategy) and another monomer binding to the terminal bases of dsRNA duplex (end-
capping strategy). 
 
NS1 protein (Hartman et al. 2004). In this regard, given that VP35 is able to bind dsRNA, it is not 
surprising that the major functional contribution to the IFN antagonism displayed by this protein 
resides in its C-terminal IID, where the dsRNA binding domain in also located (Cárdenas et al. 
2006). As stated above, according to the proposed model, VP35 would block the induction of IFN-
α/β by sequestering viral dsRNA to RIG-I recognition, and several observations strongly support 
the reliability of this interpretation. In fact, the mutation into alanine of basic residues R305, K309 
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and R312, which are located within the RBD, caused failure of dsRNA binding as well as loss of IFN 
inhibition without affecting VP35 replicative function (Hartman et al. 2004; Hartman et al. 2006; 
Hartman, Ling, et al. 2008). Upon infection with these mutant viruses, animals became protected 
by subsequent exposure by wild type EBOV, to which normally would have succumbed (Prins, 
Delpeut, et al. 2010). VP35 exerts its inhibition of RIG-I-mediated induction of IFN-α/β also by 
molecular mechanisms that are independent by its dsRNA binding function. In fact, given that this 
protein was found able to interact with the kinase domain of the TBK-1/IKK-ε complex and that it 
suppressed the activation of IFN-β promoter mediated by the overexpression of these two 
kinases (Prins et al. 2009), it is likely that VP35 may act as an alternate substrate for IFN kinases, 
thereby hampering the phosphorylation of IRFs. VP35 was also recently shown to hijack the host 
Small Ubiquitin-like Modifier (SUMO) machinery to accomplish extensive SUMOylation of IRFs 
(Chang et al. 2009). Through direct interaction with SUMO E2, Ubc9, PIAS1 and E3 ligase, and 
subsequent recruitment onto this complex of IRF-7 and IRF-3, VP35 promotes SUMOylation of 
these IRFs which, in turn, results in the transcriptional repression of type I IFN (Chang et al. 2009). 
In addition to suppression of the RLRs activation and RLR-mediated production of IFN-α/β, it is 
emerging that EBOV VP35 antagonizes the host cell defence targeting a variety of other antiviral 
mechanisms. In fact, VP35 was found to abolish the PKR-induced shutdown of protein translation, 
probably inhibiting the phosphorylation of its eIF2-α (Feng et al. 2007; Schümann et al. 2009). 
Moreover, VP35 has been shown to act as a suppressor of the RNA interference (RNAi) pathway. 
During EBOV infection RNAi is activated by the production of virus-specific dsRNAs, which are 
processed into 21 nucleotide long small interfering RNAs (siRNAs) by Dicer, an RNAse III-like 
endonuclease. Subsequently, siRNA is unwound, and one strand of this duplex, the guide-strand, 
is incorporated into the RNA-induced silencing complex (RISC). This complex, formed by TRBP 
and PACT proteins, uses the siRNA guide-strand to target viral mRNAs bearing complementary 
sequences. According to the model proposed, VP35 would overcome antiviral RNAi response by 
suppressing the RISC processing of siRNAs. In particular, VP35 interacts with Dicer and its two 
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partners TRBP and PACT, thereby subtracting RISC from approaching to siRNAs. Notably, given 
that these two members of the RISC also interact with and activate PKR, their sequestration 
might explain how VP35 suppresses PKR activity, given that a physical interaction between this 
kinase and VP35 was not detected (Fabozzi et al. 2011). 
 
1.3.2. IAV NS1 protein 
IAV replication, spread and pathogenesis are highly dependent on the function of NS1 protein 
(Basler & Aguilar 2008). Among the key features of NS1 is its capacity for RNA binding, including 
to dsRNA (Chien et al. 2004). One of the consequences of NS1 binding to dsRNA is to bind and 
sequester viral dsRNAs from detection by 2’-5’ OAS (Min & Krug 2006). Activated OAS synthesizes 
2’-5’ oligoadenylates, which in turn stimulate latent RNase L, leading to viral RNA degradation 
(Silverman 2007). NS1 also binds and inhibits the activity of protein kinase R (PKR), inhibiting the 
PKR-dependent phosphorylation of eIF-2α and thereby avoiding shutdown of viral protein 
synthesis by PKR (Min et al. 2007). Other important roles of NS1 include binding to the 30 kDa 
subunit of cleavage and polyadenylation specificity factor (CPSF30), and also to poly(A)-binding 
protein II (PABPII) (Chen et al. 1999; Kuo & Krug 2009). These activities lead to inhibition of 3’-end 
processing of cellular pre-mRNAs and prevention of their nuclear export, including IFN mRNAs 
synthesized in response to viral infection. Further inhibition of cellular mRNA export is achieved 
by the interaction of NS1 with components of the nuclear pore complex (Satterly et al. 2007). 
Finally, NS1 has been shown to interact directly with TRIM25, an E3 ubiquitin ligase responsible for 
activation of RIG-I, which normally leads to downstream signalling and stimulation of the IFN 
response (Ludwig & Wolff 2009). NS1 binds to TRIM25, inhibits RIG-I ubiquitination and thus 
prevents the synthesis of cellular IFN (Gack et al. 2009). 
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1.3.2.1. IAV NS1: the gene and the protein 
The IAV genome consists of eight single-stranded negative sense RNA segments that encode 10 
or 11 viral proteins, depending on the strain. All of the proteins are structural proteins except for 
NS1 and PB1-F2. The NS1 protein is designated as non-structural protein because it is synthesized 
in infected cells, but is not incorporated into virions (Palese & Shaw 2007). This protein is coded 
by segment 8, which also encodes nuclear export protein (NEP, previously termed NS2) from a 
spliced mRNA. (Lin et al. 2007). Regulation of splicing is controlled, in part, by the viral NS1 protein 
itself and may represent a mechanism for auto-regulation of protein levels within infected cells.  
NS1 has a strain-specific length of 230–237 aa and an approximate molecular mass of 26 kDa 
(Palese & Shaw 2007). NS1 is divided into two distinct functional domains: an N-terminal RNA-
binding domain (residues 1– 73) (Fig. 8a), which in vitro binds with low affinity to several RNA 
species in a sequence independent manner, and a C-terminal ‘effector’ domain (residues 74–230) 
(Fig. 8b, c), which predominantly mediates interactions with host-cell proteins, but also 
functionally stabilizes the RNA-binding domain (Wang et al. 2002). The RNA-binding domain alone 
is a symmetrical homodimer with each monomer consisting of three α-helices. Dimerization is 
essential for binding dsRNA and the stoichiometry of dimer:dsRNA is 1:1 (Chien et al. 2004). Two 
identical helices from each NS1 monomer contribute towards dsRNA-binding by forming 
antiparallel ‘tracks’ on either side of a deep cleft. The ‘tracks’ consist of conserved basic and 
hydrophilic residues that appear to form complementary contacts with the polyphosphate 
backbone of dsRNA (Fig. 8d) (Yin et al. 2007). Residues in NS1 that mediate this interaction 
include T5, P31, D34, R35, R38, K41, G45, R46 and T49 (Yin et al. 2007). It should be noted that 
alanines are commonly substituted for both R38 and K41 in many experimental studies in order to 
abrogate the RNA-binding activity of NS1 (Fig. 8a). Crystallographic studies revealed that the C-
terminal effector domain of both a human and avian NS1 protein (residues 74–230) can 
independently homodimerize, with each monomer consisting of seven β-strands and three α-
helices (Benjamin G Hale et al. 2008). Within each monomer, the β-strands form a twisted, 
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crescent-like, anti-parallel β-sheet around a long, central α-helix. There is currently no structure 
available for the C-terminal ~25 amino acids of NS1, a region which is involved in many strain-
specific functions. The precise dimeric assembly of the NS1 effector domain has yet to be fully 
established, as two dimer conformations have been proposed: strand–strand (Bornholdt & 
Prasad 2006), and helix–helix (Benjamin G Hale et al. 2008) (Fig. 8b, c). Amino acids involved at 
both dimer interfaces appear reasonably well-conserved; however, biochemical evidence 
indicates that W187 (a residue located at the helix–helix interface) is essential for dimerization of 
an avian NS1 effector domain in solution (Benjamin G Hale et al. 2008). This suggests that the 
helix–helix dimer, at least for the avian NS1 protein used, is likely to be biologically relevant (Fig. 
8b, c). Interestingly, recent data suggest that a third dimeric state of the NS1 effector domain also 
probably exists (PDB ID: 2RHK). As a full-length NS1 protein structure has yet to be determined, 
the actual conformation of the complete NS1 dimer may differ significantly from that already 
published for the two individual domains (Benjamin G. Hale et al. 2008). 
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Figure 15. Structure of the IAV NS1 protein. (a) Cartoon ribbon representation of the dimeric RNA-binding domain 
(residues 1–73). R38 and K41, which are critical for RNA-binding, are highlighted. (b) and (c) Cartoon ribbon 
representations of the two proposed effector domain dimerization conformations. (b) Residues 83–202 (helix–helix 
dimer). (c) Residues 79–207 (strand–strand dimer). W187, which has been shown experimentally to be essential for 
dimerization of the avian NS1 protein effector domain, is highlighted in both structures. (d) Structure of NS1 RNA-
binding domain (residues 1-70) bound to dsRNA phosphate backbone. For all structures (a–d), monomers are coloured 
blue and yellow. Images were prepared using PyMol (PDB files: 1NS1, 2GX9, 3D6R, 2ZKO). 
 
1.3.2.2. IAV NS1 function as antagonist of the innate immune system 
Several studies have attempted to demonstrate how NS1 acts to limit the production of IFN-β. 
Current evidence indicates that NS1 proteins limited IFN-β induction by both pre-transcriptional 
(cytoplasmic) and post-transcriptional (nuclear) processes (Benjamin G. Hale et al. 2008). Studies 
using NS1 of Influenza A/Puerto Rico/8/34 (IAV PR8) demonstrated that this protein prevents 
dsRNA- and virus-mediated activation of the IRF-3, NF-κB and c-Jun/ATF-2 transcription factors, 
which are otherwise essential for IFN-β induction (Talon et al. 2000; Ludwig et al. 2002). Such 
inhibition was shown to occur pre-transcriptionally, and to require two residues in NS1 that 
strongly contribute to RNA-binding: R38 and K41 (Talon et al. 2000) (Fig. 8a). Recent work 
indicates that PR8 NS1 may mediate its pre-transcriptional block on IFN-β induction by forming a 
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complex with RIG-I (Pichlmair et al. 2006; Mibayashi et al. 2007). Co-precipitation of RIG-I with 
PR8 NS1 is dependent upon R38 and K41 in PR8 NS1, suggesting that these two residues are 
involved in a potential protein–protein interaction, or that RNA acts as an intermediary 
component (Pichlmair et al. 2006). General inhibition of nucleo-cytoplasmic transport of all 
poly(A)-containing mRNAs was one of the first functions ascribed to NS1 and it was suggested 
that direct binding of NS1 to the 3’ poly(A) tail of mRNAs was the mechanism by which this 
inhibition occurred (Qiu & Krug 1994). However, viral mRNAs are not prevented from leaving the 
nucleus of infected cells, despite them having a poly(A) tail. Therefore, interactions between NS1 
and proteins directly involved in mRNA maturation and nucleo-cytoplasmic transport may play the 
greater and more specific role in cellular mRNA export inhibition (Benjamin G. Hale et al. 2008). 
Influenza virus A/Udorn/72 (Ud) has been extensively used to model the nuclear inhibition of 
cellular pre-mRNA processing by NS1. The C-terminal effector domain of Ud/ NS1 binds directly to 
two zinc-finger regions in the 30 kDa subunit of cleavage and polyadenylation specificity factor 
(CPSF30) and interacts with poly(A)-binding protein II (PABPII) (Chen et al. 1999; Kuo & Krug 
2009). The Ud/NS1–CPSF30 complex is thought to prevent CPSF30 from binding cellular pre-
mRNAs, thereby inhibiting normal cleavage and polyadenylation of the 3’-end of host-cell mRNAs. 
As polyadenylation of influenza A virus mRNAs is independent of cellular 3’-end processing 
factors, viral mRNAs are not affected by CPSF30 inhibition. Furthermore, the interaction of 
Ud/NS1 with PABPII may specifically block the nuclear export of fully processed mRNAs that 
partially escape 3’-end formation inhibition. Viral mRNAs must overcome this global block on 
nucleo-cytoplasmic transport; however, it is still unclear how this occurs. NS1 can directly block 
the function of two cytoplasmic antiviral proteins: 2’-5’ OAS (Min & Krug 2006), and the dsRNA-
dependent serine/threonine PKR (Min et al. 2007). A predominant function of the NS1 RNA-
binding domain is to out-compete OAS for interaction with dsRNA, thereby inhibiting this host 
antiviral strategy. Given the role of RNase L in augmenting the production of IFN-β (Silverman 
2007), it is possible that NS1-mediated OAS inactivation also contributes to suppression of IFN-β 
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synthesis (Talon et al. 2000). NS1 binds to a linker region in PKR, and prevents a conformational 
change that is normally required for release of PKR auto-inhibition. Such a mechanism allows NS1 
to circumvent both dsRNA- and PACT-mediated inhibition of translation by PKR (Li et al. 2006). 
NS1 has been proposed to inhibit the induction of RNAi, but a functional role for NS1 in RNAi-
antagonism during virus infection awaits clarification (Matskevich & Moelling 2007). 
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1.4. Aim of the research 
Owing to the inhibitory functions exerted by the VP35 protein, EBOV is able to efficiently evade 
the innate immune response and replicate undisturbed. Therefore, VP35 is a key factor for EBOV 
virulence and pathogenicity, feature that makes it a valid drug target. 
The aim of the research work presented in this thesis is focused on the development of strategies 
to overrun EBOV VP35 inhibitory functions of the IFN signaling cascade. In chapter 2 is presented 
the realization of a new miniaturized method able to reproduce the dsRNA-dependent RIG-I-
mediated IFN-β induction signaling pathway, in order to evaluate and characterize EBOV VP35 
inhibitory properties. Using this method with the aim to find new countermeasures against EBOV 
VP35 functions two different approaches were exploited. The first approach, described in chapter 
3, is the attempt to identify VP35 target site/s suitable to design small molecules that bind VP35 
dsRNA binding site and inhibit this function. The second approach, described in chapter 4, is the 
attempt to identify small molecules (of natural and/or synthetic origins) that, not physically 
interacting with VP35, could potentiate or activate the IFN signalling pathway, increasing the IFN 
production in response to viral infections up to a level sufficient to subvert VP35 inhibition. 
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2.0. A LUCIFERASE REPORTER GENE ASSAY TO MEASURE EBOLA VIRUS VP35 INHIBITION 
OF THE DSRNA RIG-I-MEDIATED IFN-β INDUCTION 
 
2.1. Introduction 
The high EVD lethality has been attributed to the ability of the virus to efficiently suppress the 
host innate antiviral response, which begins with the recognition of viral dsRNA by the 
cytoplasmic PRR RIG-I inducing type I IFN response. As previously described in Chapter 1, this 
induction is prevented by EBOV VP35 protein that, in the signal cascade that leads to type I IFN 
production, acts i) binding viral dsRNA and mimicking RIG-I recognition of 5’-ppp dsRNA (Zinzula 
& Tramontano 2013), ii) interfering with the activation of IRF-3 (Basler et al. 2000; Basler et al. 
2003; Hartman, Bird, et al. 2008; Prins et al. 2009) and iii) inhibiting PACT-induced RIG-I ATPase 
activity by preventing RIG-I interaction with PACT (Luthra et al. 2013). Site-directed mutagenesis 
studies demonstrated that EBOV VP35 is a validated drug target by being involved in several 
processes that are crucial for successful virus replication and propagation (Prins, Binning, et al. 
2010; Mitchell & Carter 2014). To characterize the role of the single EBOV VP35 functions in 
inhibiting the RIG-I signaling cascade leading to IFN-β production and to identify small molecules 
that could interfere with VP35 properties, a cell-based system able to quantify dsRNA IFN-β 
induction and its inhibition by EBOV VP35 is essential. IAV NS1 protein also strongly inhibits RIG-I-
mediated IFN-β induction and a luciferase reporter gene assay has been used to assess its 
properties (Rückle et al. 2012), even though it was not suitable for drug development. Therefore, 
we established a luciferase reporter gene assay to assess EBOV VP35 inhibition of RIG-I-mediated 
IFN-β induction. We miniaturized and characterized the assay that can be used to evaluate EBOV 
VP35 properties as well as the efficacy of small molecules that can act as VP35 inhibitors. 
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2.2. Materials and Methods 
 
2.2.1. Cell lines 
A549 and MCDK cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco) 
supplemented with 10% fetal bovine serum (FBS) (Gibco), 1% Penicillin-Streptomycin (Pen/Strept) 
(EuroClone). Cells were incubated at 37 °C in a humidified 5% CO2 atmosphere. 
 
2.2.2. Construction of EBOV VP35 mammalian expression plasmid 
To introduce the EBOV VP35 gene into a mammalian expression vector, we amplified the EBOV 
VP35 gene Zaire species (1976 Yambuku-Mayinga strain), previously cloned in the pET45b-ZEBOV-
VP35 vector (Zinzula et al. 2009), by polymerase chain reaction (PCR). Two primers were designed 
to amplify the gene and introduce it into the mammalian expression vector construct by BamHI 
and NotI restriction enzymes. Primer sequences were: 5’-
TCAGCAGAGGATCCGATAATGCATCACCACCACCATCAC-3’ and 5’-
GTACTAATATGCGGCCGCTCAAATTTTGAGTCCAAGTGT-3’. PCR reaction was carried out in a mixture 
containing: pET45b-ZEBOV-VP35 plasmid (100 ng), each primer (400 μM), MgCl2 (1.5 mM), each 
dNTP (0.2 mM) and 0.025 μl FideliTaq™ DNA Polymerase (Usb). The PCR mixtures were filled with 
nuclease-free water to a final volume of 50 μL and the PCR cycle consisted of: an initial 
denaturation at 94 °C for 2’, 35 cycles of denaturation at 94 °C for 30”, annealing at 55 °C for 30”, 
extension at 68 °C for 2’, and a final extension at 68 °C for 5’. The amplified EBOV VP35 gene and 
the pcDNA3 plasmid (Invitrogen) were digested by BamHI and NotI restriction enzymes (New 
England BioLabs), linear pcDNA3 plasmid was dephosphorylated with Antarctic Phosphatase 
(New England BioLabs) and fragments (50 ng of linear pcDNA3 and 20 ng of insert VP35) were 
ligated by T4 DNA ligase (New England BioLabs) to obtain the pcDNA3-ZEBOV-VP35 plasmid that 
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was transformed to the E. Coli Top 10 strain by standard heat shock protocol at 42 °C for 90”. 
Plasmid was extracted and sequenced for control. 
 
2.2.3. IAV PR8 propagation 
MDCK cells were infected with IAV/Puerto-Rico/8/34 (IAV PR8) strain with a MOI of 0.001 in 
Infectious DMEM with 0.2% bovine serum albumin (BSA) (Sigma Aldrich), 1% Pen/Strept, 0.01% 
Ca/Mg solution and 3 μg/ml of trypsin at 37 °C for about 56 hours. The medium was collected in a 
falcon and centrifuged at 3000 x g for 10 min at 4 °C. The virus present in the supernatant is 
aliquoted and frozen at -80 ° C. 
 
2.2.4. IAV PR8 titration 
MDCK cells were seeded in a 6-well multiwell plate and treated with serial dilutions (1:10) of a IAV 
PR8 aliquot in Infectious PBS with 0.2% BSA, 1% Pen/Strept and 0.01% Ca/Mg solution at 37 °C for 30 
min. The inoculum was aspirated and the Plaque medium with 3% Agar was added. The plate was 
incubated at 37 °C for about 72 hours. 1 ml of 3.6% formaldehyde is added to each well for 1 hour 
and then washed with water. The lysis plaques were highlighted by Crystal violet staining. 
 
2.2.5. IAV PR8 RNA extraction 
For production of viral RNA (vRNA), A549 cells were infected with IAV PR8 with a MOI of 5 in 
Infectious PBS for 30 min. The inoculum was aspirated and the Infectious DMEM was added. 5 
hours post infection the total RNA was isolated using the RNeasy Kit (Qiagen). 
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2.2.6. Luciferase reporter gene assay 
A549 cells (5 x 104 per well) were transfected in 48-well plates with T-Pro P-Fect Transfection 
Reagent (T-Pro Biotechnology) with the construct pGL IFN-β luc kindly provided by Prof. Stephan 
Ludwig (Institute of Molecular Virology, Münster, Germany). Twenty-four hours after transfection 
cells were additionally transfected with IAV PR8 vRNA and incubated for further 6 hours at 37 °C 
with 5% CO2. Cells were harvested with lysis buffer (50 mM Na-MES pH 7.8, 50 mM Tris-HCl pH 7.8, 
1 mM dithiothreitol, 0.2% Triton X-100). The crude cell lysates were cleared by centrifugation and 
50 µL of cleared lysates were added to 50 µL of luciferase assay buffer (125 mM Na-MES pH 7.8, 
125 mM Tris-HCl pH 7.8, 25 mM magnesium acetate, 2.5 mg/ml ATP) in a white 96-well plate. 
Immediately after addition of 50 µL 1 mM D-luciferin into each well, the luminescence was 
measured in Victor3 luminometer (Perkin Elmer). The relative light units (RLU) were normalized as 
the fold activity of the unstimulated control. Each assay was carried out in triplicate. 
 
2.2.7. EBOV VP35 luciferase reporter gene inhibition assay 
The above described luciferase reporter gene assay was used with the co-transfection of the pGL 
IFN-β luc plasmid with the pcDNA3-ZEBOV-VP35. When IAV NS1 was used as control, the 
mammalian expression plasmid pcDNA3-NS1, kindly provided by Prof. Stephan Ludwig (Institute 
of Molecular Virology, Münster, Germany) was co-transfected with the pGL IFN-β luc plasmid. 
Inhibition of luciferase expression was indicated as percentage of induced control. Each assay 
was carried out in triplicate. 
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2.3. Results 
2.3.1. Miniaturization of the luciferase reporter gene assay in 48-well plates 
When viral 5’-ppp dsRNA is accumulated into the cytoplasm of infected cells, its presence is 
recognized by RIG-I that induces a signaling cascade finally leading to the expression of IFN-β. This 
cytokine acts then in both autocrine and paracrine manner to induce the expression of a number 
of proteins coded by the ISGs that, in turn, suppress viral propagation. EBOV VP35 inhibits the 
RIG-I-mediated IFN-β induction (Basler et al. 2000) and this ability has been previously measured 
with a luciferase reporter gene assay in which IFN-β induction was stimulated by Sendai virus 
(SeV) infection (Basler et al. 2000; Basler et al. 2003; Hartman et al. 2004; Cárdenas et al. 2006; 
Prins et al. 2009; Daisy W Leung et al. 2010; Prins, Binning, et al. 2010), a method that strongly 
limits its range of use. Therefore, we wanted to establish a more suitable assay that could mimic 
the viral dsRNA IFN-β induction and could be used for drug screening. A 12-well plates method 
using A549 cells that were transiently transfected with a luciferase reporter gene construct (pGL 
IFN-β luc) driven by the IFN-β enhanceosome, a promoter element that contains all principal 
transcription factor binding sites of the IFN-β promoter was previously reported (Rückle et al. 
2012; Hillesheim et al. 2014). In this assay, the transfection of Influenza virus A/Puerto Rico/8/1934 
viral RNA (IAV PR8 vRNA) into A549 cells containing pGL IFN-β luc plasmid activates the RIG-I 
signaling cascade leading to a luminescent signal (System 1, Fig. 16). Such method was not 
suitable for drug development, therefore in order to apply this system to evaluate EBOV VP35 
inhibitory functions for drug development purposes, we firstly needed to verify if we could 
miniaturize it. The PAMP chosen in our experiments to unleash the innate antiviral response, as 
mentioned above, is the vRNA of IAV PR8. To propagate this virus the MDCK cells was used to 
replace the conventional method which involves the use of chicken embryos. The use of this cell 
line derives from its ability to rapidly replicate in simple culture conditions and especially from the 
lack of an antiviral response which would interfere with the virus multiplication. The MDCK cells 
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were infected with a MOI of 0.001. The choice of a low MOI is essential for viral particles 
replication and propagation, which occurs at 37 °C during about 56 hours, until the cytopathic 
effect (CPE) shows an increase of 70%. The virus that was present in the supernatant was 
aliquoted and frozen at -80 ° C. To determine the viral titre of the prepared stock a plaques assay 
was used. The MDCK were seeded in a 6-well plate and treated with serial dilutions from an IAV 
PR8 aliquot to quantify. The culture was incubated for about 72 hours, during which the virus 
cytopathic effects occurring through the plaques lysis formation highlighted by the Crystal violet 
addition. IAV PR8 vRNA stocks were prepared by in vitro infection of A549 cells with IAV PR8 and 
subsequent purification of ribonucleic acid. The A549 cell line was infected at MOI 5 for 5 hours at 
37 ° C. During the 5 hours of incubation, the ssRNA genomes were replicated and accumulated 
inside the infected cells, also in dsRNA form as replicative intermediate. The purification of viral 
RNA from the cell lysate was performed with silica-membranes. Once obtained the PAMP, we 
evaluated the IFN-β activation by vRNA transfection in 48-well plates and performed a time-
course to assess the timing to optimize RLU signaling (Fig. 17a). Results showed that a minimum 
of 6 hours was needed to obtain a sufficiently strong RLU signal. Secondly, we asked which was 
the optimal timing for an efficient vRNA transfection and performed a vRNA transfection time-
course, observing that the minimum time for an efficient transfection was 3 hours (Fig. 17b). 
Thirdly, to further optimize the assay, we asked which were the optimal amounts of luciferase 
plasmid and vRNA to be transfected into each 48-well. Hence, A549 cells were initially transfected 
with various amount of pGL IFN-β luc (125, 250 and 500 ng per well) and after 24 hours cells were 
additionally transfected with various amount of IAV PR8 vRNA (75, 125, 250 and 500 ng per well). 
Luciferase activity was measured 6 hours post transfection. Results showed that optimal 
concentrations for both reporter vector and vRNA were 250 ng (Fig. 17c). We also tried to further 
miniaturize the assay using 96-well plates, however the RLU signal was not sufficiently consistent 
to allow a reproducible use (data not shown). 
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Figure 16. Stimulation of innate immune response: System 1. In System 1, the recognition of PAMP triggers the signal 
cascade that will lead to the activation of IFN-β promoter that will produce luciferase. After 6h stimulation, cells are 
harvested. 50 μl of cell extracts are added to 50 μl of luciferase assay buffer and immediately after injection of 50 μl 1 
mM D-luciferin into each sample, the luminescence is measured with a luminometer. 
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Figure 17. Miniaturization of the luciferase reporter gene assay in 48-well plates. (a) A549 cells were transfected with 
pGL IFN-β luc and 24 hours post transfection cells were additionally transfected with IAV vRNA. Cells were lysed 
respectively after 1, 2, 3, 4, 5 and 6 hours and the luciferase activity was measured. (b) A549 cells were transfected with 
pGL IFN-β luc and 24 hours post transfection cells were additionally transfected with IAV vRNA and the medium was 
changed respectively after 1, 2, 3, 4, 5 and 6 hours and luciferase activity was measured. (c) A549 were transfected with 
125 ng, 250 ng and 500 ng of pGL IFN-β luc and 24 hours post transfection cells were additionally transfected with 75, 
125, 250 and 500 ng of IAV vRNA. 6 hours post transfection cells were lysed and luciferase activity was measured. 
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2.3.2. Inhibitory effect of EBOV VP35 and IAV NS1 in the luciferase reporter gene assay in 48-well 
plates 
Once developed the system, we asked whether this 48-well assay could be used to evaluate the 
ability of EBOV VP35 to inhibit the RIG-I-mediated IFN-β induction as measured by a lower 
production of luciferase as compared to the dsRNA stimulated control. We subcloned the EBOV 
Zaire strain VP35 gene from the bacterial expression vector pET45b-ZEBOV-VP35 (Zinzula et al. 
2009) into the mammalian expression vector pcDNA3. Firstly, using two primers to add BamHI 
and NotI cleavage sites at the ends of the VP35 gene (Fig.18a); secondly, amplifying by PCR (Fig. 
18b) and finally, cutting the PCR product and the vector pcDNA3 with these enzymes and carrying 
out the ligase reaction. The outcome of the ligation reaction was checked by further digestion 
and electrophoresis (Fig.18c). Since it is known that IAV NS1 protein strongly inhibits RIG-I-
mediated IFN-β production (Rückle et al. 2012) we used IAV NS1 as control. The reporter vector 
was co-transfected with various amounts of pcDNA3-VP35 or pcDNA3-NS1 (10, 45, 180, 750 and 
3000 ng) leading to different levels of viral protein expressions inside the cells (data not shown) 
(System 2, Fig. 19). Results showed a dose-dependent inhibition of the dsRNA stimulated RIG-I-
mediated IFN-β production by both EBOV VP35 and IAV NS1 (Fig. 20). It is worthwhile to note that, 
at all plasmid concentrations, EBOV VP35 showed an inhibitory effect higher than the one shown 
by IAV NS1, suggesting that EBOV VP35 could be more efficient than IAV NS1 in inhibiting innate 
immune activation. 
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Figure 18. EBOV VP35 gene subcloning into mammalian expression vector. (a) To add the BamHI and NotI cleavage site 
at the 5'- and 3'-ends of the VP35 gene respectively, two primers were designed. (b) The VP35 gene was amplified by 
PCR. (c) The amplified product and the pcDNA3 vector were cut with the restriction enzymes and were subjected to 
ligation reaction. After ligated product transformation in E. coli and extraction of the amplified plasmid, it was digested 
with the same restriction enzymes to check the VP35 gene insertion in the plasmid.  
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Figure 19. Stimulation inhibition of innate immune response: System 2. In System 2, the response will be inhibited by 
the presence of the viral proteins, NS1 or VP35, produced through transfected plasmid. After 6h stimulation, cells are 
harvested. 50 μl of cell extracts are added to 50 μl of luciferase assay buffer and immediately after injection of 50 μl 1 
mM D-luciferin into each sample, the luminescence is measured with a luminometer. 
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Figure 20. Inhibitory effect of EBOV VP35 and IAV NS1 in the luciferase reporter gene assay in 48-well plates. A549 
cells were co-transfected with 250 ng of pGL IFN-β luc and various amount (10, 45, 180, 750 and 3000 ng) of pcDNA3-
VP35 or pcDNA3-NS1. 24 hours post transfection cells were additionally transfected with 250 ng of IAV vRNA and after 
additional 6 hours cells were lysed and luciferase activity was measured. 
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2.4. Discussion. 
In 2014 the largest Ebola outbreak in West Africa resulted in tens of thousands of victims and 
raised great concerns as it compromised public health systems and led to social disruptions. Cases 
of EVD have also been reported in both USA and Europe, further increasing the level of public 
awareness for EVD diffusion threat. Development of drugs that can inhibit EBOV replication and 
counteract EVD progression is therefore a global health priority. EBOV VP35 is a valid drug target, 
since it is one of the most potent weapons that EBOV uses to evade the innate immune antiviral 
response (Basler et al. 2003; Hartman, Bird, et al. 2008; Prins, Binning, et al. 2010; Daisy W. Leung 
et al. 2010). In fact, EBOV VP35 interferes at various levels of the RIG-I-mediated signaling cascade 
that leads to the type I IFN production, allowing undisturbed viral multiplication. We have 
previously obtained a full-length recombinant version of the EBOV VP35 protein (Zinzula et al. 
2009) and have characterized its dsRNA binding function using a newly established in vitro 
magnetic pull down dsRNA binding assay (Zinzula et al. 2012). However, to assess the specific role 
that each VP35 function has in inhibiting the RIG-I-mediated signaling cascade as well as to screen 
for potential inhibitors, it was required the establishment of a robust and reproducible cellular 
assay that could measure the dsRNA induced RIG-I signaling pathway activation. Until now, 
methods used to analyze VP35 effects on IFN-β promoter activation utilized cellular infection with 
SeV as innate immunity stimulus (Basler et al. 2000; Basler et al. 2003; Hartman et al. 2004; 
Cárdenas et al. 2006; Prins et al. 2009; Daisy W Leung et al. 2010; Prins, Binning, et al. 2010). This 
technique requires up to 24 hours of stimulation to measure the luminescence signal and a more 
complex experimental approach, including virus manipulation. In addition, SeV infection does not 
activate only the RIG-I-mediated signaling pathway, which is the major VP35 target, eventually 
leading to IFN-β promoter activation through other pathways. An alternative more manageable 
method used IAV dsRNA transfection as a stimulus for the activation of RIG-I signaling pathway 
that culminates in IFN-β production (Hillesheim et al. 2014). Therefore, we modified this assay by 
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miniaturizing it from 12-well to 48-well plates, a format more suitable for small molecules 
screening, and optimized the assay condition which only requires 6 hours of stimulation. 
Subsequently, we showed that EBOV VP35 expression can inhibit the dsRNA induced RIG-I-
mediated IFN-β activation dose-dependently, demonstrating that the assay can be used to 
identify EBOV VP35 inhibitors. Noteworthy, when compared with NS1, EBOV VP35 inhibitory 
efficacy was greater at higher transfected plasmid concentrations. More studies however should 
be performed to assess if EBOV can suppress innate immunity activation more effectively than 
IAV. Overall, we described the establishment of a new cell-based method to characterize EBOV 
VP35 properties related to its inhibition of the RIG-I-mediated IFN-β induction and to identify small 
molecules that can interfere with these properties. 
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3.0. DEFINITION OF KEY RESIDUES IN DSRNA RECOGNITION AND IFN-ANTAGONISM OF 
EBOLA VIRUS VP35 FOR DRUG DEVELOPMENT 
 
3.1. Introduction 
As described in Chapter 1, EBOV VP35 IID forms an asymmetric dimer held together by a network 
of hydrogen bonds with dsRNA-end independently of the nucleotide sequence: one monomer 
binds the sugar-phosphate backbone of both dsRNA strands and the second binds to dsRNA 
terminal bases and the proximal phosphate backbone. Together, the backbone-binding and the 
end-capping binding VP35 monomers mimic the RLRs shape and hide their recognition site at 5’-
ppp dsRNA ends (Cárdenas et al. 2006; Leung et al. 2009; Daisy W Leung et al. 2010; Kimberlin et 
al. 2010; Ramanan et al. 2012; Bale et al. 2013; Zinzula & Tramontano 2013). The crystallographic 
structures provide structural basis to understand dsRNA binding-mediated inhibition of IFN 
response by EBOV VP35, also revealing the relative contribution of several amino acids for this 
function, showing differences in contribution between the two RBD/IIDs. For instance, side chains 
of amino acid residues R312 and R322 (EBOV numbering) are in the backbone-binding RBD/IID 
monomer involved in protein-protein interactions at the dimer interface, whereas the same 
residues undertake interactions with dsRNA in the end-capping RBD/IID. Similarly, amino acid 
residues such as F239, Q274, I278, K339 and I340 interact with dsRNA backbone in the backbone-
binding monomer, whereas they bind to dsRNA terminal bases in the end-capping one (Daisy W 
Leung et al. 2010; Kimberlin et al. 2010). Moreover, the importance of VP35 RBD/IID residues like 
R305, K309, R312, K319, R322, F239 and K339 has been highlighted by previous mutagenesis 
studies, which showed decrease or loss of dsRNA binding function (Cárdenas et al. 2006; Leung et 
al. 2009; Daisy W Leung et al. 2010; Prins, Delpeut, et al. 2010; Zinzula et al. 2012) as well as 
diminished or abolished suppression of IFN-β induction (Hartman et al. 2004; Cárdenas et al. 2006; 
Hartman, Bird, et al. 2008; Hartman, Ling, et al. 2008; Leung et al. 2009; Daisy W Leung et al. 2010; 
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Prins, Delpeut, et al. 2010).  In addition to end-capping, total coat of dsRNA has been described in 
three more recent crystallographic structures of EBOV VP35 RBD/IID and the one of closely 
related Marburg virus (MARV) (Bale et al. 2012; Ramanan et al. 2012; Bale et al. 2013). Shielding all 
available RLRs activation sites along the nucleic acid helix in addition to the sole dsRNA termini 
amplifies the extent of VP35 anti-IFN capabilities, reinforcing the importance of VP35 dsRNA 
binding function as antiviral target. However, given the difficulties in inhibiting the VP35 binding 
to a wide and non-specific surface of dsRNA backbone, on the one hand, and the specificity of 5’-
ppp recognition, on the other hand, led us to focus on targeting the small surface of VP35 end-
capping site that has potentially more implications for small molecule inhibitors design. We 
previously developed a biochemical assay to assess dsRNA binding ability of EBOV full length 
recombinant VP35 (rVP35) (Zinzula et al. 2009; Zinzula et al. 2012) and a reporter gene assay that 
evaluates the IFN-antagonist ability of EBOV VP35 expressed in A549 cell line (Chapter 2). Hence, 
in order to define their impact on dsRNA end-capping, we performed a structure-based alanine 
scanning mutagenesis of rVP35 residues involved in this interaction. The data collected, together 
with computational studies, allowed the identification of a defined site, important for prospective 
drug design against immune suppression function of EBOV VP35. 
 
3.2. Materials and methods 
For cell lines, mammalian expression plasmids and luciferase reporter gene inhibition assay used 
see Materials and methods in Chapter 2. 
 
3.2.1. EBOV VP35 wt and mutant plasmids 
Cloning of the EBOV VP35 gene into pET45b(+) vector (Novagen) to obtain the pET45b-ZEBOV-
VP35 plasmid was previously described (Zinzula et al. 2009). The QuickChange II Site-Directed 
Mutagenesis kit (Agilent technologies) was used to obtain corresponding mutant plasmids by 
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introducing in the EBOV cDNA VP35 gene sequence previously described single point mutations 
R305A, K309A, R312A (Zinzula et al. 2012) and new mutations F239A, S272A, Q274A, L277A, I278A, 
Q279A, I280A, T281A, K282A, K319A, R322A, K319A/R322A and K339A. 
 
3.2.2. Expression and purification of full-length wt and mutants EBOV rVP35 
Full-length, wt and mutants, bacterially-expressed rVP35s were obtained as previously described 
(Zinzula et al. 2009). Briefly, protein expression was carried out on transformed E. coli BL21AI 
(Invitrogen) cultured in LB media at 37 °C and induced at an optical density of 0.6 OD at 600 nm 
with 0.4% L-arabinose (Sigma-Aldrich). rVP35s were IMAC purified with Ni-Sepharose High 
Performance (GE Healthcare) beads by using a BioLogic LP FPLC system (Biorad), and dialyzed in 
desalting buffer (50 mM sodium phosphate pH 7.5, 300 mM NaCl, 10% glycerol, 0.014% β-
mercaptoethanol). As previously published (41), rVP35 full-length proteins were purified at ≈95% 
homogeneity, their integrity was assessed by PAGE analysis and their concentration was 
calculated using the Protein Quantification kit-Rapid (Fluka). 
 
3.2.3. Differential scanning fluorimetry analysis 
Differential scanning fluorimetry (DSF) analysis was carried out in a MiniOpticon real-time PCR 
instrument (BioRad) by using the Protein Thermal Shift Dye kit (Life technologies) according to 
manufacturer’s instructions. Measurements were performed using excitation λ = 470-505 nm and 
emission λ = 540-700 nm and data were acquired on a temperature gradient from 25 °C to 95 °C 
with increments of 0.5 °C. Samples contained 2 µg rVP35 protein, 1X SYPRO Orange (Life 
technologies), 50 mM sodium phosphate pH 7.5, 150 mM NaCl and 20 mM MgCl2 in a 20 µL final 
volume. Fluorescence data were analyzed, and the derivative of the curve representing melting 
temperature (Tm) of wild type and mutants rVP35 was obtained by using the CFX manager 
software v.2.1 (BioRad) tool for protein thermal shift assays protocols. 
 
78 
 
3.2.4. dsRNA in vitro transcription and dsRNA labeling 
Heterologous 500 bp dsRNA was produced by in vitro transcription using the T7 MEGAscript RNAi 
kit (Ambion) from the linearized DNA provided with the kit, according to manufacturer’s 
instructions. The 500 bp labeled dsRNA was generated by supplementing the in vitro 
transcription reaction with 0.15 µCi of 3HGTP (35.5 Ci/mmol) (Perkin–Elmer). The DNA control 
template provided by Ambion was used to generate, by standard PCR protocols, other two 
linearized DNA templates to in vitro transcribe the 150 and 50 bp dsRNA as above. All in vitro 
transcribed (IVT) dsRNA molecules were purified from transcription reaction with the MEGAclear 
kit (Ambion) or with Quick Spin G25 columns (Roche), and quantified by spectrophotometry. The 
integrity of DNA templates and IVT dsRNA molecules was assessed by agarose-gel 
electrophoresis. 
 
3.2.5. Magnetic pull down assay 
The rVP35-dsRNA complex formation was assessed exploiting the properties of the TALON 
paramagnetic Dynabeads (Invitrogen). Firstly, 1 μg of rVP35 was conjugated to 50 μL TALON 
beads in a volume of 700 μL of binding/washing buffer (50 mM sodium phosphate pH 7.5, 150 mM 
NaCl, 0.05% Tween-20) for 15 min at 23 °C under gentle rotating agitation (20 rpm). Unconjugated 
rVP35 was removed by magnetic field application, supernatant removal and further washing with 
binding/washing buffer. Pellets with conjugated rVP35 were re-suspended in a 100 μL volume of 
binding/washing buffer containing 20 mM MgCl2 and 1.5 nM 500 bp 3H-dsRNA (0.1 Ci/mmoles), 
then incubated for 60 min at 37 °C (20 rpm). Unbound 3H-dsRNA was separated by the conjugated 
rVP35-dsRNA complex by magnetic field application and supernatant removal. A further washing 
step was performed to completely remove unbound 3H-dsRNA. 3H-dsRNA elution was performed 
by incubation of the beads pellet in 300 μl elution buffer (binding/washing buffer plus 1 M 
imidazole pH 7.5) for 10 min at 23 °C (20 rpm), subsequent magnetic field application and 
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supernatant removal. The supernatant was transferred to vials and radioactivity was determined 
with a Beckman LS 6500 beta-counter (Beckman-Coulter). 
 
3.2.6. Molecular Systems Preparation 
The coordinates of VP35-dsRNA homodimer structure were taken from the RCSB Protein Data 
Bank (PDB ID: 3L25) (Daisy W Leung et al. 2010). The protein was prepared by using the Maestro 
GUI Protein Preparation Wizard module (Schrödinger LLC. 2014. Maestro GUI, New York, NY, 
USA). Bond orders and formal charges were added for hetero groups, and all the hydrogen atoms 
were added in the structure. After preparation, the structures were refined to optimize the 
hydrogen-bond network by using OPLS2005 force field (Banks et al. 2005). The minimization was 
terminated once the energy converged or the RMSD reached a maximum cut off of 0.30 Å.  Wild 
type (wt) model was generated introducing 5’-ppp dsRNA as terminal portion using build module 
in Maestro GUI available in Schroedinger Suite 2014 (Schrödinger LLC. 2014. Maestro GUI, New 
York, NY, USA). The protein was then minimized Polak-Ribiere conjugate gradient minimization 
allowing 10000 iteration and a convergence threshold of 0.01 in GB/SA implicit water (Still et al. 
1990). Since the model misses the coil-coil tail portion and dsRNA is likely to be open during the 
simulation, force constraints were applied around residue Asp218 and dsRNA terminal bases (C1-
G8). The rest of the complex was left free to move. Minimized complex was then used as initial 
structure for MD simulation, where the same constraints were maintained. Mutants were 
generated based on wild type structure by mutating the corresponding residues.  
 
3.2.7. Molecular Dynamics Simulations and MM-GBSA Calculations 
MacroModel of Schrödinger Suite Software (Mohamadi et al. 1990) was applied to carry out 
molecular dynamics simulations (3ns) including the energy minimization and equilibration 
protocols (200ps). The production phase runs 3ns. The binding free energy calculations were 
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performed by MM/GBSA (Kollman et al. 2000) method using extracted snapshots from 
equilibrated trajectories. Binding free energy was computed: 
∆Gbind = Gcomplex –Gprotein -GRNA 
The free energy G, can be calculated using the scheme as follows: 
∆G = ∆EMM + ∆Gsol -T∆S, ∆Gsol  
and ∆S are considered approximately similar for all similar complex therefore ∆G is proportional 
to ∆E: 
∆EMM = ∆Eint + ∆Eele + ∆Evdw 
The average energies of MD simulation are listed in Table 4 while Fig. 26 shows DE and the most 
important contributions to the energy of binding: electrostatic (∆Eele) and  van der Walls (∆Ewdw). 
The resulting complexes were considered for the binding modes graphical analysis with Maestro 
(Schrödinger LLC. 2014. Maestro GUI, New York, NY, USA) and Pymol (Delano WL 2002). 
 
3.2.8. Sample preparation for crystallization studies 
The insert for VP35 I278A mutant IID was generated by amplifying the coding region for VP35 IID 
(residues 215-340) from the full length VP35 I278A mutant sequence. The amplified PCR product 
was cloned into a modified pMAL vector (New England Biolabs) containing a 6x Histidine tag, a 
maltose binding protein (MBP) fusion tag and a tobacco etch virus (TEV) protease recognition site 
N-terminal to the multiple cloning site. The HisTag-MBP-VP35 I278A IID plasmid was transformed 
into E. coli BL21 (DE3) cells (Novagen). VP35 1278A IID was expressed as previously described 
(Leung et al. 2009). Briefly, the transformed cells were grown in LB medium with 50 μg/ml of 
Ampicillin at 37 °C until they reached an OD600 of 0.4-0.6. The cells were then induced with 0.5 mM 
IPTG overnight at 22 °C and harvested by centrifugation at 16700 x g for 25 min The cell pellets 
were stored at -80 °C. The cells were thawed and resuspended in lysis buffer (25 mM sodium 
phosphate pH 7.0, 1 M NaCl, 5 mM β-mercaptoethanol) with 50 μg/ml of DNase, and 1 tablet of 
Complete EDTA-free protease inhibitor (Roche). After being lysed by sonication on ice, the cells 
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were clarified by centrifugation at 30000 x g for 45 min. The clarified lysate was loaded onto a 5 
ml HisTrap HP column (GE Healthcare), pre-equilibrated with binding buffer containing 25 mM 
sodium phosphate pH 7.0, 150 mM NaCl, 10 mM imidazole, 5 mM β-mercaptoethanol. The protein 
was eluted with a 40% linear gradient from Buffer A (25 mM Sodium phosphate pH 7.0, 150 mM 
NaCl, 20 mM Imidazole, 5 mM β-mercaptoethanol) to Buffer B (25 mM Sodium phosphate pH 7.0, 
150 mM NaCl, 1 M Imidazole, 5 mM β-mercaptoethanol). Affinity tag removal was performed by 
adding 3 mg of TEV protease to the elution fractions and dialysing overnight at 4 °C against 25 mM 
Sodium phosphate pH 7.0, 150 mM NaCl, 5 mM Imidazole, 5 mM β-mercaptoethanol. Digestion 
efficiency was assessed by SDS-PAGE. In order to effectively remove the HisTag-MBP 
contamination, the digested protein was loaded onto a 5 ml HisTrap HP column connected in 
series with a 5 ml MBPTrap HP column (GE Healthcare), both pre-equilibrated with binding buffer, 
collecting the unbound protein. A final purification step was performed by size-exclusion 
chromatography (SEC) on a HiPrep 16/60 Sephacryl S-100 HR column (GE Healthcare) in 
crystallization buffer (10 mM HEPES pH 7.0, 150 mM NaCl, 2 mM TCEP). The purest fractions (> 90% 
purity), as assessed by SDS-PAGE, were concentrated to 9 mg/ml, flash frozen and stored at -80 
°C. 
 
3.2.9. Crystallization and structure determination 
Crystallization trials were set up on INTELLI-PLATE low profile 96 well plates (Art Robbins 
Instruments) using the sitting drop method on a Crystal Gryphon Liquid Handling System (Art 
Robbins Instruments). Each crystallization drop contained 150 nl or 350 nl of protein at 9 mg/ml 
and 150 nl of crystallization buffer from commercially available screens. The crystallization plates 
were incubated at 20 °C. One high-resolution dataset (1.9 Å) was collected in house at 100 K on a 
Rigaku-MSC Micromax-007 X-ray generator and Saturn 944+ CCD detector. The crystal was grown 
under condition H2 of the Index Screen (Hampton Research). The crystal was previously mounted 
on a CryoLoop (Hampton Research) and cryo-protected by sequentially submerging the loop in 
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crystallization buffer (0.2 M potassium sodium tartrate tetrahydrate, 20% polyethylene glycol 
3350) with 10% and 20% glycerol. Data collection and refinement statistics are shown in Table 5.  
The dataset consisted of 360 images and was processed with iMOSFLM (Leslie 2006). The space 
group was reindexed from P222 to P212121 in Reindex (Bernardinelli & Flack 1985), in the CCP4 
suite (Winn et al. 2011). Model building and initial structure refinement were performed with 
Phaser (McCoy et al. 2007) and REFMAC5 (Winn et al. 2011; Murshudov et al. 1997). Structure 
determination was obtained by molecular replacement using the wild-type VP35 IID structure 
(PDB entry: 3FKE) as a search model. The water molecules were previously removed from the 
search model using CHAINSAW (Winn et al. 2011; Stein 2008). After several cycles of rigid body 
and restrained refinement in REFMAC5, further structure refinement was performed with Phenix 
(Adams et al. 2002), alternated with model inspection and manual refinement in Coot (Emsley & 
Cowtan 2004). The resulting model was validated with Coot and MolProbity (Lovell et al. 2003). 
The structure images were generated with PyMOL (Delano WL 2002). 
 
3.3. Results 
3.3.1. dsRNA binding property of Ebola VP35 end-capping mutants 
In agreement with the VP35 RBD/IID dimeric complex model present in literature (Daisy W Leung 
et al. 2010; Kimberlin et al. 2010), a more recent work described a kinetic in which dsRNA binding 
by the end-capping RBD/IID monomer constitutes the earliest binding event, to which attachment 
of backbone-binding RBD/IID monomers all along the dsRNA helix follows (Bale et al. 2013). 
Within this picture, it is the small area interacting with dsRNA terminal bases in the concave 
surface of the end-capping RBD/IID monomer that represents the most suitable target for small 
molecule inhibitors design. Moreover, selected amino acid residues laying in this area, like F239, or 
surrounding it, such as R312, K319, R322 and K339 were found critical for RBD/IID dsRNA binding 
and IFN inhibition, as their mutation into alanine resulted in decrease, or even total loss, of those 
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functions (Hartman et al. 2004; Cárdenas et al. 2006; Hartman, Ling, et al. 2008; Hartman, Bird, et 
al. 2008; Leung et al. 2009; Daisy W Leung et al. 2010; Zinzula et al. 2012; Prins, Delpeut, et al. 2010; 
Bale et al. 2012). In our previous effort to characterize a bacterially-expressed full length EBOV 
rVP35 (Zinzula et al. 2009), we also investigated the impact of rVP35 mutants at residues involved 
in dsRNA backbone interactions, namely R305A, K309A and R312A, on dsRNA binding ability 
(Zinzula et al. 2012). Here, we wanted to explore the effect of alanine substitutions at residues 
involved in dsRNA end-capping and, to this aim, we performed alanine-scanning in vitro site-
directed mutagenesis of rVP35 residues F239, L277, I278, I280 (hydrophobic), S272, Q274, Q279, 
T281 (polar uncharged), K282, K319, R322, K319/R322 and K339 (polar charged) (Fig. 21).  
 
Figure 21. Important residues in end-capping interface. VP35 residues involved in end-capping interaction which can be 
subjected to structure-based alanine scanning. 
 
Firstly, once all rVP35 mutants were purified as previously described (Fig. 22b) (Zinzula et al. 
2009), to assess their proper folding and exclude that any difference in dsRNA binding might 
have been imputable to major structural perturbations, we performed a DSF analysis comparing 
 
84 
 
the thermal stability of full length wt and mutants rVP35 (Fig. 22a). Interestingly, all rVP35 
mutants showed melting temperature (Tm) values comparable to wt rVP35 (59.4 ± 0.6 °C), which 
suggests maintenance of proper folding and no structural perturbations beyond the minimal 
local change (Table 2). Secondly, by using a previously described magnetic pull down assay 
(Zinzula et al. 2012), we assessed the dsRNA binding activity of rVP35 mutants through an 
homologous-competition binding curve titration with an in vitro transcribed (IVT) 500 bp dsRNA 
as ligand. Results showed that EBOV rVP35 end-capping mutants were impaired in dsRNA 
binding function, having no measurable Kd values or even poorly detectable activity with 
percentages ranging from 0.8% to 6% of bound dsRNA with respect to wt rVP35 (Fig. 23a). Only 
exceptions were, Q274A, R322A and K319A/R322A rVP35 mutants, which were able to bind the 
IVT 500 bp dsRNA but showed lower affinity with increased Kd values with respect to wt rVP35 
(Fig. 23b). In particular, Kd values for Q274A, R322A and K319A/R322A rVP35 mutants were 5.23 ± 
1.8 nM, 9.13 ± 1.5 nM and 15.62 ± 2.0 nM, respectively. According to these data, rVP35 dsRNA 
binding activity was seriously compromised by the change of a single amino acid residue in the 
end-capping binding surface. Next, to assess repercussion of those mutations on VP35 IFN-
antagonism, we asked whether these residues would play a critical role in the IFN-inhibition 
activity of EBOV VP35 in cell cultures. 
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Figure 22. Assessment of thermal stability and folding state of rVP35 wt and mutants. (a) Melting curves 
featuring low initial fluorescence and a sigmoidal shape indicative of protein unfolding transition and first 
derivative of fluorescence emission data for the DSF analysis of wt and mutants rVP35. The maximum value of 
the curves, which represent the midpoint of the unfolding transition, or Tm, reveal that all rVP35 proteins share 
comparable thermal stability and folding state. (b) Coomassie blue-stained 12% SDS-PAGE analysis showing 
that IMAC purified full length rVP35 wt and mutants were all expressed at similar levels. 
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Table 2. Thermal stability of wt and mutants rVP35. Tm values obtained by DSF analysis on rVP35 wt and 
mutants. Data shown are the mean ± SD of three independent experiments performed in triplicate samples. 
VP35 protein Tm [°C] 
wt 59.4 ± 0.6 
F239A 59.7 ± 0.2 
S272A 59.0 ± 0.4 
Q274A 60.6 ± 0.6 
L277A 58.8 ± 0.5 
I278A 61.3 ± 1.2 
Q279A 60.0 ± 0.6 
I280A 56.5 ± 0.9 
T281A 58.3 ± 0.6 
K282A 59.4 ± 0.3 
K319A 58.2 ± 0.6 
R322A 60.3 ± 1.0 
K319A/R322A 58.0 ± 0.4 
K339A 59.2 ± 0.5 
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Figure 23. dsRNA binding ability of EBOV rVP35 backbone and end-capping mutants. (a) Relative dsRNA binding 
activity of rVP35 backbone (white dotted) and end-capping (black dotted) mutants expressed as percentage of the 
total amount of dsRNA bound by wt rVP35: R305A, 81.0%; K309A, 38.0%; R312A, 27.0%; F239A, 0.8%; Q274A, 39,6%; I278A, 
5.0%; Q279A, 6.0%; K319A, 2.4%; R322A, 36.1%; K319A/R322A, 9.2%; K339A, 2.9%. (b) Homologous-competition binding, 
performed with the magnetic pull down assay at 37 °C with optimal biochemical conditions, showed that Q274A (red 
circle), R322A (empty red square) and K319A/R322A rVP35 (red triangle) bind to 500 bp IVT dsRNA with lower affinity 
with respect to wt rVP35 (full grey circle). Concentration of unlabelled competitor dsRNA is plotted versus the bound 
percentage of the radiolabeled dsRNA ligand, each experimental point is the mean ± SD of specific bound dsRNA from 
three independent experiment. 
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3.3.2. IFN-β inhibition property of EBOV VP35 end-capping mutants 
EBOV VP35 interferes at various levels the RIG-I-mediated signaling cascade that leads to the type 
I IFN production, ultimately allowing uncontrolled viral replication (Zinzula & Tramontano 2013). 
To assess the effect of end-capping mutations on the ability of EBOV VP35 in suppress type I IFN 
induction in cellular systems, we used the reporter gene assay described in Chapter 2 that uses 
IAV dsRNA transfection as a stimulus for RIG-I signaling pathway culminating in the activation of 
the IFN-β promoter. As described in chapter 2, when A549 cells were co-transfected with IFN-β 
reporter vector and increasing amounts of plasmid expressing EBOV VP35 wt or mutants there is 
a dose-dependent inhibition of the dsRNA-stimulated, RIG-I-mediated IFN-β production by EBOV 
VP35 wt (Fig. 24). Hence, we tested the IFN-antagonism ability of EBOV VP35 end-capping 
mutants transfecting the VP35 carrying plasmids at different concentration to assess the relative 
impairment of the mutant VP35s IFN-antagonism function. Since the assay herein used is different 
from those previously described, we firstly assayed VP35 mutants R305A, K309A and R312A to 
properly compare our results with those previously reported (Hartman et al. 2004; Cárdenas et al. 
2006; Leung et al. 2009; Hartman, Ling, et al. 2008). The obtained results on these three mutants 
showed that K309A have a moderate and R312A a significant reduction in IFN-antagonist activity, 
while R305A does not affect this function, confirming previous reports (Hartman et al. 2004; 
Cárdenas et al. 2006) (Fig. 25). Secondly, we tested all other VP35 mutants showing that F239A, 
S272A, Q274A, L277A and Q279A VP35 mutants substantially maintained an IFN-antagonist ability 
comparable to the one showed by wt VP35 (Fig. 25). Differently, I278A, I280A, T281A, K319A, 
K339A mutants exhibit a strong reduction in IFN-antagonism ability, particularly statistically 
significant at lower VP35 mutant plasmid concentrations, suggesting that these VP35 mutants can 
compensate dsRNA binding affinity reduction at higher protein concentrations. Most relevantly, 
similarly to R312A VP35, K282A and R322A VP35s showed the strongest reduction in VP35 IFN-
antagonist ability, statistically significant even at the highest tested VP35 plasmid concentration 
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transfected (Fig. 25). An exception case is the one of K319A/R322A VP35 mutant that showed a 
reduction of the IFN-antagonist ability only at the intermediate plasmid concentrations. The dose 
dependent inhibition of the vRNA RIG-I pathway activation allowed to determine the plasmid 
concentration required to reduce the IFN-β promoter induction by 50%, ICp50 value, for all tested 
VP35s. Given the wt VP35 ICp50 value of 110 ± 4.9 ng, I278A, I280A, T281A, K319A, and K339A VP35s 
exhibited a significant increase in their ICp50 values comprised in the range of 150-170 ng (p < 
0.05), while R312A, K282A and R322A mutants exhibited higher ICp50 values (517 ± 28.2 ng, 584 ± 
49.4 ng and 663 ± 60.3 ng respectively) with p < 0.05, demonstrating the criticality of these three 
single amino acid mutations for the inhibitory activity of the protein (Table 3). It is worth to note 
that 2 out of 3 VP35 mutants that showed the strongest reduction in IFN-antagonist efficacy in 
cell-based assays, R312A and R322A, maintained an although reduced capability of binding dsRNA 
in biochemical assays. Differently, other VP35 mutants such as F239A, S272A, Q274A, L277A, I278A, 
I280A, T281A, K319A, and K339A that showed no or limited reduction of their IFN-antagonist 
efficacy in cell-based assays almost completely lost their dsRNA binding ability in biochemical 
assays. A number of reasons could be involved to explain these observations: i) some of the 
mutated VP35 amino acid residues,  such as F239, Q274, I278 and K339, participate in both end-
capping and backbone-binding VP35 monomers; ii) it is not clear at the moment if the magnetic 
binding assay with rVP35 involves monomeric, dimeric, multimeric (or a mixture of them) VP35 
forms, and whether these forms have different responses to alanine scanning mutagenesis; iii) 
some of the mutated VP35 amino acid residues participate in both protein–RNA and protein–
protein interactions with cellular proteins involved in the RIG-I pathway and the loss of one of the 
two functions is not sufficient to impair the VP35 inhibition. In any case, since the overall 
biochemical and cellular analysis of the results showed that a number of the selected VP35 amino 
acid residues such as I278A, I280A, T281A, K282A, K319A, K319A/R322A and K339A significantly 
reduced VP35 ability to inhibit vRNA induced RIG-I pathway activation, we asked whether it could 
be possible to integrate these data with a computational study to analyze the effect of mutations 
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in a molecular basis to identify a site potentially useful to the basis for further drug development. 
In particular we wanted to investigate the contribution of these mutations on the two VP35 
monomeric binding surfaces, to select residues more selectively involved in the EBOV VP35 dsRNA 
binding function. 
 
 
 
Figure 24. The dose dependent inhibition of the vRNA RIG-I pathway activation by EBOV VP35 wild type.  A549 cells 
were co-transfected with 250 ng of pGL IFN-β luc and various amount (1.6, 8, 40, 200 and 1000 ng) of pcDNA3-ZEBOV-
VP35 wild type. 24 hours post transfection cells were additionally transfected with 250 ng of IAV vRNA and after 
additional 6 hours cells were lysed and luciferase activity was measured. Inhibition of luciferase expression was 
indicated as percentage of induced control. The error bars indicate standard deviation from three independent 
experiments. 
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Figure 25. Luciferase reporter RIG-I-mediated IFN-β activation gene assay inhibition of EBOV VP35 wild type and 
mutants. A549 cells were co-transfected with 250 ng of pGL IFN-β luc and 1000, 200, 100 and 40 ng of pcDNA3-ZEBOV-
VP35 wild type and end-capping mutants. 24 hours post transfection cells were additionally transfected with 250 ng of 
IAV vRNA and after additional 6 hours cells were lysed and luciferase activity was measured. Inhibition of luciferase 
expression was indicated as percentage of induced control. Data are average of three independent experiments, with 
error bars representing standard deviation (* p value < 0.05). 
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Table 3. wt and mutant EBOV VP35s IFN-β promoter induction inhibition. 
VP35 protein aICp50 [ng] 
wt 110 ± 4,9 
R305A 88 ± 15,5 
K309A 146 ± 4,8 
R312A 517 ± 28,2 
F239A 143 ± 1,9 
S272A 59 ± 8,1 
Q274A 89 ± 1,8 
L277A 85 ± 9,4 
I278A 151 ± 0,5 
Q279A 100 ± 8,2 
I280A 157 ± 11,4 
T281A 166 ± 6,2 
K282A 584 ± 49,4 
K319A 169 ± 6,3 
R322A 663 ± 60,3 
K319A/R322A 177 ± 16,8 
K339A 173 ± 17,3 
 aTransfected plasmid concentration required to reduce the IFN-β promoter induction by 50%.  
 
93 
 
3.3.3. Computational studies 
In recent years, molecular dynamics (MD) simulations combined with binding free energy 
calculations have been applied successfully to understand the behavior of protein complex 
structures in solution (protein-ligand, protein-protein, protein-RNA interactions) and guide the 
drug design (Liu & Yao 2010). Therefore we investigated with computational studies - performed 
with the support of Dr. Simona Distinto, Department of Life and Environmental Sciences, 
University of Cagliari - the molecular basis of the effects of selected amino acid mutations. We 
have first investigated the effect of 5’-ppp portion. We add the triphosphate moiety to the 
crystallographic model (Daisy W Leung et al. 2010). Once minimized, the complex VP35-dsRNA 
was subject to MD simulation finding the formation of a more stable complex compared to the 
original one without 5’-ppp portion (-197 kcal/mol vs -175 kcal/mol) that confirms previous 
experimental studies that reveal the importance of 5’-ppp (Zinzula & Tramontano 2013). In fact, 
5’-ppp during the simulation appears stabilized by an array of hydrophobic, H bonds and ionic 
interactions. Given that this modified model could properly assess EBOV VP35 selectivity for 5’-
ppp-dsRNA versus dsRNA, we was used it as starting point for all successive MD simulations 
where single amino acids (except double mutated K319A/K322A) have been mutated in alanine. 
During a MD simulation the molecular dynamics trajectories was monitored from the 
convergence of the root-mean square deviation of all atoms of EBOV VP35-dsRNA complexes. All 
systems resulted stable during MD simulation (Fig. 26). The overall Root-Mean Square Deviation 
(RMSD) fluctuated in a range of 0.5 nm, indicating that the system was stabilized. All mutants 
maintained the backbone conformation of wt EBOV VP35 free and in complex with dsRNA. This 
confirmed the observations done by crystallographic experiments reported in PDB [K312A, PDB: 
3L27; K339A, PDB:3L28 (Daisy W Leung et al. 2010); K319A/R322A, PDB:3L29 (Prins, Delpeut, et al. 
2010)]. MD analysis showed, for all VP35 mutants, a decreased energetic stability of the 
complexes, given the energy increase with respect to wt (Table 4). Decomposing the binding free 
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energy into different items we found that electrostatic component provides the main driving 
force of binding affinity (Fig. 27).  
 
Figure 26. MD simulations. Root-Mean Square Deviation (RMSD) of VP35–dsRNA complexes during MD simulations. All 
systems resulted stable during MD simulation. 
 
Table 4. Energetic stability of wt and mutants EBOV VP35-dsRNA complexes. All mutations showed a decreased 
energetic stability of the complexes, given the energy increase with respect to wt. 
 
ΔE (kcal/mol) ΔEmut - ΔEwt 
Wild-type -197,20 
 
I278A -195,79 -1,41 
L277A -193,87 -3,32 
T281A -190,23 -6,96 
R312A -190,22 -6,98 
K319A -188,56 -8,64 
S272A -182,84 -14,36 
F239A -170,47 -26,73 
K339 -168,92 -28,28 
K319A/R332A -167,48 -29,72 
Q274A -164,11 -33,09 
R305A -163,68 -33,52 
R322A -157,58 -39,62 
I280A -155,31 -41,89 
K309A -148,88 -48,32 
K282A -143,18 -54,02 
Q279A -140,81 -56,39 
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Figure 27. Decomposition of the binding free energy (∆E). Calculated averages of ∆E and its components (∆vdw and 
∆ele) expressed in kcal/mol of the wild type and mutated VP35–dsRNA complexes, based on the snapshots of MD 
trajectories. 
 
This could be easily interpreted since most of the mutated important residues have electrically 
charged side chains. The only exceptions are I278A, I280A and T281A. These three mutants are not 
associated to particular electrostatic changes and MD simulations showed only subtle differences 
in side chain conformations. Therefore their importance must be attributed to the loss of contacts 
with dsRNA. Hence, we investigated i) the contacts loss between the mutant VP35s  and the 
whole dsRNA (Fig. 28a), ii) the loss of contact between the single mutated amino acid in both 
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chains A and B together (Fig. 28b) and iii) for single chain A (backbone binding, Fig. 28c) and chain 
B separately (end-capping binding, Fig. 28d). The analysis of the overall loss of contacts showed 
that all mutations are associated to detrimental of contacts with dsRNA (Fig. 28a). The 
decomposition analysis between the loss of contacts of backbone vs end-capping binding 
monomers did not show a univocal behavior for all residues. However, for K282A and K322A VP35 
mutants the loss of affinity for dsRNA is surely due to loss of contacts between these two 
residues in Chain B and dsRNA (Fig. 28d). In addition MD analysis showed that other residues that 
impaired VP35 affinity for dsRNA such as K319, I280 and T281 were not involved directly with 
interactions with dsRNA; however, their localization in chain B was closer to dsRNA with respect 
to chain A, therefore their mutations in end-capping position appear to be more important that in 
backbone-binding. Overall, we can conclude that the effects of mutation of B-chain residues 
involved in end-capping binding is more important than the effect of the same residues involved 
in backbone binding. 
 
Figure 28. Number of contacts loss between the mutated enzyme and dsRNA. (a) Loss of good contacts with dsRNA 
for specific MD. (b) Loss of good contacts with dsRNA for specific residue mutated. (c) VP35 RBD loss of good contacts 
with dsRNA for specific residues mutated in chain A (backbone-binding). (d) VP35 RBD loss of good contacts with 
dsRNA for specific residues mutated in chain B (end-capping-binding). 
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3.3.4. Crystallographic structure of EBOV VP35 I278A mutant 
The effect of mutations of charged VP35 residue (K312, K319/K322 and K339) was studied also by 
crystallographic analyses. These studies showed that their mutation do not modify the 
conformation of the protein but the loss of affinity for dsRNA is due to changes in the 
electrostatic surface potential (Daisy W Leung et al. 2010). Since our alanine scanning study 
showed that some important residues are not charged (I278, I280 and T281), we decided to 
crystallize the RDB of the I278A VP35 mutant - with the collaboration of Dr. Valeria Fadda of 
School of Biology, University of St Andrews, UK - to verify what could be the effect of this 
mutation in terms of conformational aspect. The crystallographic structure of the I278A VP35 
mutant RBD was solved to 1.9 Å and compared to the previously published structures of the wt 
RDB VP35 (Leung et al. 2009; Daisy W Leung et al. 2010). The structure of the I278A VP35 mutant 
and the wt VP35, with or without dsRNA (PDB entry: 3L25 and 3FKE respectively), were 
superimposed in order to examine any changes in the overall structure and in the end-capping 
surface. Overall, the I278A VP35 mutant RBD alone did not exhibit significant structural changes 
when compared to wt VP35 RDB alone (Fig. 29, 30a), with a C-alpha RMSD of 0.2 Å between I278A 
RBD and the wt RDB. However, when comparing the I278A VP35 mutant RBD structure with the 
wt one in complex with dsRNA (RMSD = 0.6 Å), it is clear that most of the changes in the side 
chains of residues involved in dsRNA-binding (e.g. R305, K309, R312, K319 and R322) occur upon 
ligand binding, as similar changes are noticeable when comparing the wt unliganded structure 
with the dsRNA complex. However, when focusing the attention on the end-capping surface (Fig. 
30b), it was possible to observe a shift in the position of the C275 side chain of the I278A VP35 
mutant. F239 also appeared to be shifted in the I278A VP35 mutant in comparison to wt VP35. 
C275 and F239 did not show any side chain alteration when comparing the wt VP35 RBD 
unliganded structure to the VP35 RDB structure in complex with dsRNA (Fig. 30c). These changes 
in the end-capping surface, in particular the shift in the C275 side chain that could cause steric 
hindrance and loss of contact with the dsRNA end, partially support the data from the dsRNA-
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binding and RIG-I-mediated IFN-β production inhibition assays. Finally, we confirmed that the 
I278A mutation does not produce any major conformational change in the protein and that its 
importance is due to the loss of contacts with dsRNA associated to the missing side chain. 
 
Figure 29. Crystallographic structure of VP35 I278A mutant. Crystallographic structure of I278A VP35 mutant dsRNA 
binding domain, with the point mutation highlighted in red. 
 
Figure 30. Structure alignment of VP35 I278A IID. Structure alignment (a) of I278A VP35 RBD (green) and wt VP35 RBD 
in complex with dsRNA (grey, dsRNA in stick representation; PDB accession code: 3L25), showing the location of the 
point mutation (sticks) in the end-capping region. A closed up view (b) of the same alignment around residues F239, 
C275, I278, revealed side chain shifts on the I278 VP35 RBD that could compromise the dsRNA binding function. F239 
and C275 did not show significant changes in position upon dsRNA binding, as shown in the structure alignment (c) of 
VP35 RBD (yellow; PDB accession code: 3FKE) and VP35 RBD in complex with dsRNA (grey). 
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Table 5. Data collection and refinement statistics. 
Data collection a 
X-ray wavelength (Å) 1.542 
Resolution range (Å) 13.9  - 1.952 (2.022  - 1.952) 
Space group P 21 21 21 
Unit cell parameters (Å, °) a = 51.75    b = 65.66    c = 72.02 
α = β = γ = 90 
No. observations 122680 (13760) 
Completeness (%) 99.92 (99.22) 
Multiplicity 6.7 (5.2) 
Rmerge (%)
b 10.4 (28.1) 
Average I/σI 11.80 (4.39) 
 
Refinement 
No. atoms 
      protein atoms 
      water molecules 
4188 
1946 
263 
Protein residues 247 
Average B-Factor (Å) 
      protein 
      solvent 
20.9 
20.0 
28.0 
R-factor c 0.1802 (0.2264) 
R-free d 0.2184 (0.2720) 
RMSD bond lengths 0.007 
RMSD bond angles 1.03 
Ramachandran favoured (%) 99 
Ramachandran outliers (%) 0 
Clashscore 5.35 
aValues in brackets correspond to the highest resolution cell 
bRmerge =∑hkl∑i|Ihkl, i –〈Ihkl 〉|/∑hkl〈Ihkl 〉 
c-dR-factor and R-free = (Σ | |Fo| - |Fc| |)/(Σ |Fo|), where the Rfree was calculated from 5% of reflections excluded from 
refinement. 
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3.4. Discussion 
As widely discussed until now, the multifunctional viral protein EBOV VP35 is a validate drug 
target since it is one of the most potent weapons that EBOV uses to evade the innate immune 
antiviral response. In the context of EBOV infection, loss of VP35 dsRNA binding and IFN-
antagonist functions results in severely impaired virus replication in cells capable of mounting an 
IFN-α/β response and also fully attenuates the virus in vivo (Hartman, Bird, et al. 2008; Prins, 
Delpeut, et al. 2010). Previous studies reported that some residues comprised in the end-capping 
domain have critical roles in dsRNA binding wt EBOV VP35 (Leung et al. 2009; Daisy W Leung et al. 
2010) and mutational studies have confirmed their implication in loss of dsRNA binding ability 
(Cárdenas et al. 2006; Leung et al. 2009; Daisy W Leung et al. 2010; Prins, Binning, et al. 2010; 
Zinzula et al. 2012) as well as in suppression of IFN-β induction (Hartman et al. 2004; Cárdenas et 
al. 2006; Hartman, Bird, et al. 2008; Hartman, Ling, et al. 2008; Leung et al. 2009; Daisy W Leung et 
al. 2010; Prins, Binning, et al. 2010). Binding experiments performed with the magnetic pull down 
assay show that minimal changes on the surface electrostatic charge in the pocket of full-length 
VP35 that houses the dsRNA terminus – such as those that may come from the alanine 
substitution of residues that interact with terminal bases or phosphate groups – may result in 
significant decrease, if not in total loss, of dsRNA binding activity in biochemical assay. In fact, 
while Q274 rVP35 mutant showed a 2-fold decreased binding affinity with respect to wt rVP35, for 
most of the tested end-capping mutants, including F239A, I278A, Q279A, I280A, T281A, K319A and 
K339A rVP35, the amount of bound dsRNA was barely detectable. Interestingly, and in substantial 
agreement with what was observed for the backbone binding R312A mutant, the absence of 
dsRNA binding activity previously reported for the R322A and K319A/R322A VP35 RBD (Daisy W 
Leung et al. 2010; Prins, Delpeut, et al. 2010) was partially restored in our full length rVP35 
proteins that bear the same mutations, even though with affinities that were respectively 3-fold 
and 5-fold lower when compared to wt rVP35. Possibly, this greater efficiency in dsRNA binding 
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displayed by full length VP35s with respect to the RBD alone may reflect the critical contribution 
of regions lacking in the sole RBD that might have a role in stabilizing or strengthening other 
domains of the protein during exertion of their function. Afterwards, through an assay that 
evaluates the dsRNA-dependent activation of RIG-I signaling pathway we found that the 
mutations I278A, I280A, R312A, K282A, T281A, K319A, R322A and K339A seems to heavily affect 
the EBOV VP35 IFN-antagonist activity, and among these the mutants R312A, K282A and R322A 
seems to exhibit a critical importance for the protein inhibitory function. Comparing the 
biochemical and cellular data, it is clear that the loss of dsRNA binding capacity by some mutants 
is not necessarily manifested in a loss of VP35 IFN-antagonism. In fact, it is known that VP35 also 
interact with the kinase domain of the TBK-1/IKK-ε complex suppressing the activation of IRF-3 
(Prins et al. 2009) and it was reported that, when the IFN-β production is activated by a dsRNA-
independent mechanism, the mutated R312A, R322A and K339A VP35 showed reduced 
suppression of IFN-β production (Cárdenas et al. 2006; Daisy W Leung et al. 2010). On the 
contrary, the mutated F239A VP35, that lost the dsRNA-binding function, preserved the dsRNA-
independent IFN-inhibitory property (Daisy W Leung et al. 2010). These results suggest that the 
loss of the dsRNA binding ability by such amino acid substitution may not impair the IRF-3 
activation inhibitory capacity, which explains the discrepancy between our biochemical and 
cellular data. Overall, therefore, we can classify these VP35 mutants in 3 categories: i) VP35 
mutants that show a reduced dsRNA binding ability in biochemical assay but retain IFN-
antagonism in cell culture assay such as F239A, S272A, Q274A, L277A and Q279A; ii) VP35 mutants 
that show a reduced dsRNA binding ability in biochemical assay as well as a reduced IFN-
antagonism in cell culture assay at lower level of protein expression but they retain IFN-
antagonism functions at higher level of protein expression such as I278A, I280A, T281A, K309A, 
K319A, K319A/R322A and K339A; iii) VP35 mutants that show a reduced dsRNA binding ability in 
biochemical assay and show a reduced IFN-antagonism in cell culture assay even at higher level of 
protein expression such as R312A, K282A and R322A. 
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Computational studies have become necessary to investigate the molecular basis of the effects of 
selected amino acid mutations. Our studies, firstly, have confirmed the possibility of modeling the 
VP35 interaction with dsRNA by showing the importance of 5’-ppp portion for a more stable 
VP35:dsRNA complex compared to the original one without 5’-ppp and, secondly, have showed 
that - investigating the contacts loss between the mutant VP35s and the whole dsRNA - the 
effects upon mutation on the monomer involved in end-capping binding seems to be more 
important than the one involved in backbone binding monomer. Moreover, it was determined 
that the electrostatic component provides the main driving force of binding affinity. In fact, the 
most of important mutated residues have electrically charged side chains with the exception of 
I278A, I280A and T281A residues that showed only subtle differences in side chain conformations. 
The high resolution crystallographic structure of VP35 I278A RBD, chosen to see the effects of this 
mutation in terms of conformational aspect, revealed some minor local changes in the dsRNA 
end-capping pocket when compared to the wt RBD, indicating that the effects of the mutation on 
dsRNA binding and IFN activation were not the result of longer range distortion of the protein. 
This further highlights the sensitivity of VP35 function to small changes in the end-capping 
domain. Overall, the set of data obtained with mutational studies with the three methods 
(biochemical, cellular and computational) allowed us to highlight the importance of some 
residues involved in end-capping binding and are localized in a delimitated area (Fig. 31), where 
the most important appear to be the R312, K282 and R322 residues. Noteworthy, the overall data 
analysis suggest that this site could be involved not only in VP35 dsRNA binding but also in VP35 
interaction with other cellular proteins involved in the RIG-I pathway. Therefore, this site seems to 
be an attractive target to develop drugs that can impede the VP35 impairment of the IFN 
activation and will be used in future virtual screening studies in order to find small molecules able 
to inhibit selectively EBOV VP35.  
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Figure 31. Hot spots of VP35 surface. Residues are colored in order of importance red (R312, K282 and R322) > orange 
(I278, I280, T281, K319 and K339) > yellow (K309 and K319/R322) > green (R305, F239, S272, Q274, L277 and Q279) 
according to p value. It is possible to highlight a binding site useful for drug design delimited by yellow circle. 
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4.0. PLANT EXTRACTS AND SYNTHETIC COMPOUNDS AS ANTAGONIST OF VP35 IFN-β 
INHIBITION FUNCTION. 
 
4.1. Introduction 
A first approach to overrun EBOV VP35 inhibitory functions of the IFN signaling cascade is to 
develop small molecules that bind to VP35 inhibiting its functions, as discussed in Chapter 3. A 
second approach is to identify small molecules that could potentiate or activate the IFN signalling 
pathway, increasing IFN production in response to viral infections to a level able to subvert VP35 
inhibition not by physically interacting with it.  Plants have always been known for their medicinal 
properties and have been used since ancient times as main healing remedy and have been often 
recently disregarded as the folk medicine traditions has lost attractions. Over the last years the 
interest for plant originated constituents is increased considerably in the attempt of identify new 
active substances with therapeutic properties. While no antiviral drug coming from plant 
constituents have been approved so far, a number of small molecules extracted from plants are 
known for their antiviral effects. Just as an example, flavonoids and anthraquinones which 
showed inhibitory activity against Herpes Simplex virus types 1 and 2 (HSV-1 and HSV-2), the 
Varicella Zooster virus (ZVZ), Hepatitis C virus (HCV) (Xiong et al. 2011; Yarmolinsky et al. 2012; 
Wahyuni et al. 2013) and HIV (Esposito et al. 2013). Among the flavonoids, also quercetin that is 
present in the Hypericum hircinum L., a plant that grows in Sardinia (an Italian Island) is able to 
inhibit the HIV-1 integrase (Vandegraaff et al. 2001). As an island, Sardinia offers the greatest 
variety of endemic plants in Europe that, due to its geographical isolation, present significant 
variations in their genetic and molecular characteristics as compared to plants grown in other 
regions. Etnopharmacological studies have shown that a number of them were used until less 
than 100 years ago in folk medicine, and some of them were reported to have therapeutic effects 
on inflammations and immune system reinforcements. Examples are Plagius flosculosus which is 
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known for its anti-inflammatory activity associated with NF-κB inhibition (Calzado et al. 2005) and 
Salvia desoleana, whose leaves are still used for the anti-inflammatory properties (Atzei Domenico 
2009) and have also showed antimicrobial activities (Peana et al. 1999). Since an increase in 
stimulus-dependent IFN response or a inhibition of EBOV VP35 IFN-antagonism can lead to a 
therapeutic action of the infection itself, in collaboration with Professor Mauro Ballero and his 
research team of the Botany section, Department of Life and Environment Sciences, University of 
Cagliari, we tested extracts of Helichrysum microphyllum ssp. Thyrrenicum and Myrtus communis 
plants to assess their anti-VP35 properties. Myrtle and Helichrysum are two Mediterranean taxa, 
present in Sardinia with different species and subspecies. Helichrysum extracts showed 
antiallergic properties derived from sterol and triterpene components. Moreover, the extracts 
showed anti-inflammatory and antimicrobial properties and were used in traditional medicine to 
treat skin diseases, eczemas, psoriasis and to encourage the epidermal regeneration process 
(Maffei Facino et al. 1988; Facino et al. 1990). The presence in Helichrysum of a phloroglucinol α-
pyrone, called Arzanol, exerts a potent inhibitory action of the HIV-1 replication and show a strong 
anti-inflammatory action (Appendino et al. 2007). Myrtle extracts showed antibacterial activity 
and its leaves were used to prepare antibiotic formulations. The main secondary metabolites 
contained in Myrtle leaves are: myrtucommulone A, a phloroglucinol with antibiotic, antibacterial 
(Appendino et al. 2002) and anti-inflammatory (Feisst et al. 2005) activity; the myrtucommulone B 
employed in the treatment of psoriasis and as antioxidant (Rosa et al. 2003); the 
semimyrtucommulone with antioxidant activity (Appendino et al. 2002). In addition, we also 
tested the biological properties of a series of compounds synthesized by the research team of 
Professor Roberto Di Santo, University of Rome "La Sapienza", developed as potential broad 
range antiviral agents. 
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4.2. Materials and Methods 
 
For cell lines and mammalian expression plasmid used, see Materials and methods in Chapter 2. 
 
4.2.1. Cytotoxicity assay of extracts and compounds tested 
For cytotoxicity tests, cell lines were seeded in 96-well plates (Spectra Plate, PerkinElmer) at an 
initial density of 105 cells/ml in DMEM, containing 10% FBS, 1% Pen/Strept, in the absence or 
presence of serial dilutions of extracts (from 100 µg/ml to 0,03 µg/ml) or compounds (from 100 
µM to 0,03 µM), along with Camptothecin, used as positive control. Plates were incubated for 72 
h at 37 °C in a humidified 5% CO2 atmosphere. Cell viability was determined adding PrestoBlue™ 
Cell Viability Reagent (Invitrogen). After 1 h at 37 °C, relative fluorescence was read with a Victor3 
(Perkin Elmer). The percentages of cell viability were based on the amount of living cells in 
compound-treated cells relative to untreated control cells (defined as 100% viability). Cytotoxicity 
graphs were then generated by plotting percentage of cell viability versus concentration of 
extracts/compounds. Using regression analysis of cytotoxicity curves (in Microsoft excel), a trend 
line that best suited the curve was selected and the corresponding equation was used to calculate 
the concentration required to reduce cell growth by 50% (CC50 value). 
 
4.2.2. IFN response induction and EBOV VP35 inhibition assays 
In order to test compounds and extracts, the luciferase reporter gene assay and the same 
inhibition assay was performed as previously described in Chapter 2. In addition, the day of 
stimulation, compounds and extracts were added to cells at known concentrations and the cells 
were transfected with IAV PR8 vRNA and incubated for 6 hours at 37 °C with 5% CO2. The results 
are shown in n-fold compared to unstimulated control (when was tested the induction increase of 
IFN-β production) or as percentage of induced control (in the inhibition assay). 
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4.3. Results 
 
4.3.1. Cytotoxicity of Myrtle and Helichrysum extracts 
The Myrtle and Helichrysum extracts were screened for cellular toxicity in order to determine 
appropriate concentrations for the following luciferase reporter IFN-β gene assays. From Myrtle 
and Helichrysum total ethanolic extracts were obtained (Helichrysum ET and Myrtle ET) from the 
laboratory of Botany of the Department of Life and Environment Sciences, University of Cagliari, 
and the volatile component was extracted by steam distillation (essential oils). Regarding the 
Helichrysum essential oil extraction, biomass was collected in two different moments: before 
(Helichrysum 1) and during (Helichrysum 2) flowering, since the volatile component is more 
sensitive to seasonal variations and can contain quali-quantitative variations of the secondary 
metabolites during plant ontogenetic cycle. These extracts were first dissolved in 100% DMSO at 5 
mg/ml stock concentration. Serial dilutions ranging from 100 to 0.03 μg/ml were tested for 
cytotoxicity assay. As detailed in Table 6, the essential oils (Helichrysum 1, Helichrysum 2 and 
Myrtle EO) of the two plants showed no cytotoxic effects on A549 cells with a CC50 > 100 μg/ml. 
Instead, the Myrtle and Helichrysum ethanolic extracts (Myrtle ET and Helichrysum ET) showed 
minimal cytotoxicity with a CC50 > 50 μg/ml. Considering these results, the initial concentration of 
30 μg/ml was chosen to investigate the effects of a possible increase of the dsRNA RIG-I-mediated 
IFN-β induction. 
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Table 6. Cell growth inhibition of A549 cell line by plant extracts. CC50 values were obtained in A549 cell line. 
Camptothecin was used as positive control. Data shown are the mean ± SD of three independent experiments 
performed in duplicate samples. 
Extract aCC50 (μg/ml) 
Helichrysum  1 
(Helichrysum microphyllum ssp. Thyrrenicum 1) 
> 100 
Helichrysum  2 
(Helichrysum microphyllum ssp. Thyrrenicum 2) 
> 100 
Helichrysum  ET 
(Helichrysum microphyllum ssp. Thyrrenicum EtOH) 
91 ± 15 
Myrtle  EO (Myrtus communis) > 100 
Myrtle  ET (Myrtus communis) 66 ± 17 
Camptothecin 0,3 ± 0,2 
 aExtract concentration required to reduce cell growth by 50%. 
 
4.3.2. Helichrysum and Myrtle extracts effects on IFN-β induction 
Sardinia provides a large variety of endemic plant species that have significant genetic and 
molecular characteristics as well as metabolites that differ from the one of plants grown in other 
areas. In particular, Myrtle and Helichrysum present particular immunogenic property, as 
mentioned previously. In that context, it becomes interesting to assess the extracts components 
effects on the IFN signaling cascade. As reported before, the extracts were assayed with serial 
dilutions starting from 30 μg/ml concentration, to ensure that marginal cytotoxic effects could 
not influence the data. Results showed that 3 μg/ml of Helichrysum 1 and 10 μg/ml of Helichrysum 
2 significantly increase the dsRNA-dependent IFN-β production from 7.2 to 8.7 folds (p value < 
0.05) (Fig. 32a) and 8.4 folds respectively (p value < 0.01) (Fig. 32b), while 3 and 1 μg/ml of 
ethanolic extract Helichrysum ET from 7.2 to 8.5 and 8.3 folds respectively (p value < 0.05) (Fig. 
32c) when compared to unstimulated control. Myrtle ET at 1 μg/ml concentration also increased 
the IFN-induction from 6.7 to 8.5 folds (p value < 0.05) (Fig. 33b), while Myrtle essential oil, Myrtle 
EO, had no impact on the system (Fig. 33a). Next, to assess repercussion of IFN-induction increase 
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on VP35 IFN-antagonism, we asked whether these extract would revert the dsRNA-dependent 
IFN-β induction inhibited by EBOV VP35. 
 
 
 
 
 
 
Figure 32. Helichrysum extracts effects on dsRNA RIG-I-mediated IFN-β induction. A549 cells were co-transfected with 
250 ng of pGL IFN-β luc. 24 hours post transfection cells were additionally transfected with 250 ng of IAV vRNA and 
were added various concentrations (30, 10, 3, 1, 0.3, 0.1 μg/ml) of extracts. After additional 6 hours cells were lysed and 
luciferase activity was measured. Results are shown in n-fold compared to unstimulated control (* p value < 0.05, ** p 
value < 0.01). 
 
 
 
 
 
 
110 
 
 
Figure 33. Myrtle extracts effects on dsRNA RIG-I-mediated IFN-β induction. A549 cells were co-transfected with 250 ng 
of pGL IFN-β luc. 24 hours post transfection cells were additionally transfected with 250 ng of IAV vRNA and were added 
various concentrations (30, 10, 3, 1, 0.3, 0.1, 0.03 μg/ml) of extracts. After additional 6 hours cells were lysed and 
luciferase activity was measured. Results are shown in n-fold compared to unstimulated control (* p value < 0.05). 
 
4.3.3. Helichrysum and Myrtle extracts effects on the IFN-β induction inhibition of EBOV VP35 
Given the data obtained, we investigated whether the increase of IFN-induction was sufficient to 
subvert the blockade of the signalling cascade operated by EBOV VP35. For this reason, the active 
concentrations of each of the 2 extracts were tested in dsRNA-dependent RIG-I-mediated IFN-β 
induction system in the presence of EBOV VP35. Results showed that, in the presence of VP35 
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(Fig. 34) the extracts concentrations tested did not significant affect the VP35 inhibition of the 
vRNA induced IFN response. 
 
 
 
 
 
Figure 34. Helichrysum and Myrtle extracts effects on the IFN-β induction inhibition by EBOV VP35. A549 cells were co-
transfected with 250 ng of pGL IFN-β luc and 100 ng of pcDNA3-EBOV-VP35. 24 hours post transfection cells were 
treated with plant extracts and additionally transfected with 250 ng of IAV vRNA. After additional 6 hours cells were 
lysed and luciferase activity was measured. Inhibition of luciferase expression was indicated as percentage of induced 
control. Error bars indicate standard deviation from three independent experiments. 
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4.3.4. Cytotoxicity of synthetic compounds 
The eight synthetic compounds (a-h) obtained from the research team of Professor Roberto Di 
Santo, University of Rome "La Sapienza", were first dissolved in 100% DMSO at 100 mM stock 
concentration and assayed with serial dilutions ranging from 100 to 0.03 μM. Some compounds 
(a, e and g) showed CC50 values > 100 μM, while the others > 90 μM (b and c) and > 70 μM (d, f and 
h) (Table 7). Considering these results, in following assays was chosen the initial concentration of 
30 μg/ml and 30 μM for extracts and compounds, respectively, to investigate the effects of a 
possible increase of the dsRNA RIG-I-mediated IFN-β induction. 
 
Table 7. Cell growth inhibition of A549 cell line by synthetic compounds. CC50 values were obtained in A549 cell line. 
Camptothecin was used as positive control. Data shown are the mean ± SD of three independent experiments 
performed in duplicate samples. 
Compound aCC50 (μM) 
a > 100 
b 92,9 ± 4,8 
c 93,1 ± 1,7 
d 78,1 ± 1,3 
e > 100 
f 72,8 ± 1,5 
g > 100 
h 79,5 ± 0,8 
Camptothecin 0,3 ± 0,2 
aCompound concentration required to reduce cell growth by 50%. 
 
4.3.5. Synthetic compounds effects on IFN-β induction 
The a-h compounds series was synthesized by the research group of Prof Roberto Di Santo, 
University of Rome "La Sapienza", as potential broad spectrum antiviral drugs. These compounds 
were tested on dsRNA-dependent RIG-I-mediated IFN-β induction, using 30, 10 and 3 μM 
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concentrations. Data showed that only compound a induced a significant increase of the dsRNA-
dependent RIG-I-mediated IFN-β induction at 10 and 3 μM concentrations from 5.8 to 7.9 and 7.5 
folds respectively, as compared to unstimulated control (p < 0.01 and p < 0.05, respectively), while 
the others compounds did not show any increase (Fig. 35a,b). Subsequently, in order to verify if 
compound a was able to induce by itself the IFN signalling cascade (even in the absence of a 
vRNA stimulus), it was tested in the same system but in the absence of the IAV RNA stimulation. 
Results showed that compound a alone does not induce the IFN response (Fig. 36). The fact that 
compound a was not able to induce IFN response by itself is very important; in fact, the 
identification of possible antiviral drugs that enhance the IFN response only during infection, 
avoiding the harmful effects of uncontrolled IFN stimulation, is a priority in the perspective of 
drug development. Next, we investigated the compound a capacity to subvert the EBOV VP35 
inhibition. 
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Figure 35. Effects of compounds a-h on IFN-β induction. Data show the effects of compound a, b, c, d (Fig. 34a), e, f, g 
and h (Fig. 34b) on dsRNA RIG-I-mediated IFN induction. A549 cells were co-transfected with 250 ng of pGL IFN-β luc. 24 
hours post transfection cells were additionally transfected with 250 ng of IAV vRNA and were added various 
concentrations (30, 10, 3 μM) of compounds. After additional 6 hours cells were lysed and luciferase activity was 
measured. The results are shown in n-fold compared to unstimulated control. Only compound a showed significant 
effects (* p value < 0.05, ** p value < 0.01).  
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Figure 36. Compound a effects on IFN-β induction. Compound a was tested in RIG-I-mediated IFN-β induction system 
with and without dsRNA stimulation. A549 cells were co-transfected with 250 ng of pGL IFN-β luc. 24 hours post 
transfection cells were additionally transfected with 250 ng of IAV vRNA, or not transfected, and were added various 
concentrations (30, 10, 3, 1, 0.3 μM) of compound a. After additional 6 hours cells were lysed and luciferase activity was 
measured. Results are shown in n-fold compared to unstimulated control (* p value < 0.05, ** p value < 0.01). 
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4.3.6. Effects of compound a on the IFN-β induction inhibition of VP35 
To assess whether the IFN-I response induction by compound a was able to counteract the EBOV 
VP35 inhibitory functions, the compound was tested on A549 cells stimulated with dsRNA in the 
presence of the viral protein. Observed data demonstrated that at 10 and 3 μM concentrations of 
compound a determined a significant percentage increase from 31.5 % of VP35 inhibited control to 
44.5% and 44.4% respectively (p value < 0.05) (Fig. 37). Hence, compound a concentrations that 
increase the IFN-response induction also showed a subverting effect against EBOV VP35 
inhibition. 
 
 
Figure 37. Compound a effects on the IFN-β induction inhibition of VP35. A549 cells were co-transfected with 250 ng of 
pGL IFN-β luc and 100 ng of pcDNA3-EBOV-VP35. 24 hours post transfection cells were treated with compound a (30, 10 
3, 1, 0.3 μM) and additionally transfected with 250 ng of IAV vRNA. After additional 6 hours cells were lysed and 
luciferase activity was measured. Inhibition of luciferase expression was indicated as percentage of induced control. 
The error bars indicate standard deviation from three independent experiments (* p value < 0.05). 
 
 
117 
 
4.4. Discussion 
The discovery of a small molecule that is able to act on the innate antiviral response, reinforcing it 
when under viral attack, represents a different approach against the inhibitory strategies 
operated by EBOV through its VP35 protein. For this purpose, we tested in our system the effects 
of two Sardinian plants extracts with particular properties, such as Myrtle and Helichrysum, and a 
series of synthetic compounds developed as potential antiviral drugs. In the system that 
evaluates the IFN induction increase, the Helichrysum and Myrtle ethanolic extracts and essential 
oils of Helichrysum, but not of Myrtle, increased the IFN-I induction. However, this IFN production 
induction did not appear to be powerful enough to overturn VP35 inhibition.  
Among the synthesized compounds a-h, only compound a showed a significant effect in 
increasing IFN-I vRNA induced production. Noteworthy, it did not stimulate the innate antiviral 
response when tested in the absence of a vRNA stimulus. Very significantly, when compound a 
was tested on VP35 inhibition it showed to be able to overcome its effects, although not 
completely. This VP35 overcoming activity, along with the fact compound a acts only under 
antiviral response induction, makes this molecule very attractive for the development of an 
antiviral drug. Further studies will need to be performed to determine the compound a target 
that, presumably, is situated in one or more components belonging to RIG-I-mediated IFN 
signaling pathway, and if its VP35 inhibition is sufficient to induce an innate immune response that 
could be effective in EVD. 
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5.0. CONCLUSIONS 
The largest Ebola outbreak in West Africa has so far caused thousands of victims raising a great 
health and social global concern. As widely discussed until now, the success of EBOV replication is 
dependent on viral inhibition of the initial innate immune responses to infection. Therefore, EBOV 
VP35 protein is a validate drug target since it is one of the most potent weapons owned by EBOV. 
In fact, EBOV VP35, interfering at various levels with the RIG-I-mediated signaling cascade that 
leads to the type I IFN production, prevents the establishment of an effective antiviral immune 
response. In order to find novel countermeasures against EBOV VP35 functions our work started 
with the establishment of a new miniaturized cell-based method to characterize EBOV VP35 
properties related to its inhibition of the dsRNA-dependent RIG-I-mediated IFN-β induction. The 
development of this method was the starting point for the exploitation of two different 
approaches against the inhibitory strategies operated by EBOV VP35.  
The first approach focused on setting the basis for the development of small molecules that bind 
to VP35 and inhibit its functions. Therefore, it was important to identify sensitive sites on the 
protein to be used as drug target. Given that EBOV VP35 forms an asymmetric dimer on dsRNA 
terms with two different binding surfaces (backbone and end-capping), through mutational 
studies performed with three methods (biochemical, cellular and computational) we obtained a 
set of data that allowed us to highlight the importance of residues R312, K282 and R322 that are 
involved in end-capping binding. These residues are localized in a delimitated area that could be 
involved not only in VP35 dsRNA binding but also in VP35 interaction with other cellular proteins 
involved in the RIG-I pathway. Therefore, the identification of this site will be used in future virtual 
screening studies in order to find small molecules able to inhibit selectively EBOV VP35. 
The second approach focused on the identification of small molecules that could potentiate or 
activate the IFN signalling pathway, increasing IFN production in response to viral infections up to 
a level able to subvert VP35 inhibition. For this purpose, were tested two Sardinian plants extracts 
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(Myrtle and Helichrysum) and a series of synthetic compounds developed as potential broad 
range antiviral drugs. On the one side, the tested extracts, even increasing IFN activation, were 
not able to subvert VP35 inhibition. On the other side, instead, the synthetic compound a 
increased IFN-induction only under antiviral response stimulation and was able to subvert VP35 
inhibition, proving to be very attractive base for the development of an antiviral agent. These two 
different strategies are an interesting starting point for further studies that should focus on: i) the 
design and synthesis of molecules to test as selective inhibitors of EBOV VP35; ii) the study of the 
mechanism of action of compound a and its derivatives inside the dsRNA-dependent RIG-I-
mediated IFN signaling pathway, in order to potentiate the IFN response and the anti-VP35 
inhibition towards the realization of new effective countermeasures against EVD. 
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